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Genomic meta-analysis has been applied to many biological problems to gain more power from 
increased sample sizes and to validate the result from an individual study. As for the study 
selection criteria, however, most literatures depend on qualitative or ad-hoc numerical methods, 
and there has not been an effort to develop a rigorous quantitative evaluation framework. In this 
thesis, we proposed several quantitative measures to assess the quality of a study for a meta-
analysis. We have applied the proposed integrative criteria to multiple microarray studies to 
screen out inappropriate studies and also confirmed the necessity of proper exclusion criteria 
using real meta-analyses. By simulation studies, we showed the effectiveness and robustness of 
the proposed criteria. Secondly, we have investigated simultaneous dimension reduction 
frameworks for down-stream genomic meta-analysis. Currently, most microarray meta-analyses 
focus on detecting biomarkers; however, it is also valuable to seek a possibility of meta-analysis 
in unsupervised or supervised machine learning, particularly dimension reduction when multiple 
studies are combined. We proposed several simultaneous dimension reduction methods using 
principal component analysis (PCA). Using five examples of real microarray data, we showed 
the information gain obtained by adopting our proposed procedures in terms of better 
visualization and prediction accuracy. In the third component, we pursued a novel approach to 
elucidate undefined disease phenotypes between interstitial lung disease (ILD) or chronic 
obstructive pulmonary disease (COPD). By applying unsupervised learning technique to both  
! ! "#!
clinical phenotypes and gene expression data obtained from well characterized large number of 
cohort, we successfully showed the existence of intermediate phenotypic group who have both 
disease characteristics and divergent phenotypes in clinical and molecular features. Public health 
importance of our findings is that we showed current clinical definitions and classification do not 
account for the large number of patients having intermediate phenotypes or less common 
features that are often excluded from clinical trials and epidemiology reports. 
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1.0 INTRODUCTION
Microarray is now de facto standard technology to reveal gene expression of tens of thousands
genes simultaneously. Since its introduction, it has been used to generate tremendous amount
of data that are accumulated in the public repositories such as NCBI Gene Expression
Omnibus [18], EBI ArrayExpress [76] and Stanford Microarray Database [95]. Despite the
huge amount of available data, the analysis of individual microarray study often suﬀers
from limited statistical power caused by small sample sizes and inconsistent result with
other related studies due to heterogeneous cohorts, data annotation or preprocessing errors
[21, 105, 44, 16].
Meta-analysis has recently gained popularity in the genomic research in light of its suc-
cessful application to traditional epidemiological and medical researches. From a recent
review paper, a total of 383 papers related to microarray meta-analysis have been published
since 2004 to end of 2010. Many microarray meta-analysis methods have been proposed to
increase statistical power for diﬀerentially expression gene detection using Fisher’s method
[25, 86], LASSO method [30], random eﬀects model [9, 101], Bayesian methods [49, 108],
rank-based methods [6, 38], and other methods [74, 64]. Recently, a statistical framework
for microarray pathway meta-analysis was also proposed [94]. Hong [37] and Campain [7]
compared performance of diﬀerent microarray meta-analysis methods and Ramasamy [84]
discussed key issues and a practical guide for performing microarray meta-analysis.
Although the advantages of genomic meta-analysis are apparent, a quantitative and
systematic approach to decide the inclusion or exclusion criteria of microarray studies for
a meta-analysis has not been pursued yet. Instead, most literatures depend on subjective
expert opinions or ad hoc criteria (e.g. microarray platforms, tissue types used or number
of sample sizes) [87, 35, 113, 68, 97, 17]. Conceptually, including a bad quality or outlying
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study in the information integration can greatly dilute strength of signal, decrease statistical
power or even distort final biological conclusions. To alleviate such potential pitfalls in
meta-analysis [23], it is necessary to develop objective inclusion/exclusion criteria.
In chapter 2, we propose quantitative measures to assess the quality and consistency of
microarray studies for meta-analysis. Specifically, we developed six quality control measures
and utilized principal component analysis (PCA) biplots and an averaged rank summary
score to assist selection of studies. We then applied the proposed methods to four exam-
ples, including brain cancer, prostate cancer, idiopathic pulmonary fibrosis (IPF) and major
depressive disorder (MDD). Impacts and eﬀectiveness of the proposed inclusioin/exclusion
criteria on the final meta-analysis results in real examples are evaluated. Additional simula-
tions were also performed to show the robustness and eﬀectiveness of proposed methods.
Another issue that current genomic meta-analysis literatures are lack of is the possibility
of down-stream statistical analysis other than usual biomarker detection or gene set enrich-
ment analyses. When it comes to the other down-stream analysis, we will investigate in
chapter 3 the simultaneous dimension reduction of multiple microarray studies using Prin-
cipal Component Analysis (PCA) by finding a common PC subspace, named as MetaPCA.
The PCA is one of the most popular techniques that enable us to explore high dimensional
data space through low dimensional projection. Each Principal Component (PC) is orderly
derived to be a linear combination of original features in that it explains as much of the
variance as possible. The first PC is chosen to have the largest variance, and the next PCs
are sequentially derived to have the largest variance in the orthogonal subspace of selected
PCs [46].
One of the many applications of PCA is to visualize high dimensional subjects in two
or three dimensional PC subspace. The derived subspace is the optimal choice to represent
as much information (variance) as possible in such a reduced dimension, i.e. it minimizes
the sum of squares of the projection errors. In many cases, this approach is very successful
[85, 92, 63, 11, 120]. In the other hand, Sparse PCA was recently proposed to attain a better
interpretation of each PC—it gives sparse loadings so that each PC can be interpretable by a
smaller set of original features. It also can be served as a good technique for an unsupervised
feature selection [47, 67, 123, 13, 115, 48, 60].
2
Another possible application of PCA is to utilize PCs as an input for other statistical
methodologies such as regression analysis or various multivariate techniques [46, 39, 53]. The
two main advantages of PC based approaches are to overcome the multicollinearity problem
which occurs when highly correlated variables are included together in an analysis and to
alleviate the curse of dimensionality which numerous multivariate methods are suﬀered from
[4, 2].
When PCA is applied to microarray data, it is hoped that the chosen PCs elucidate the
informative low dimensional manifold such as interesting patterns or clusters of subject or
genes. However, microarray data is noisy, and PCA is prone to outliers; often time we fail
to get an eﬀective representation in the reduced dimension. Moreover, when we have several
similar studies and try to compare several PCA results in parallel, each PC subspace is not
comparable. An intuitive approach is to project new data sets to the given PC subspace.
However, this approach is not eﬃcient in that it fails to utilize all information from available
data sets and not robust in that it depends totally on the quality of target PC subspace.
Better approaches should be the ones that can use all information and is robust such that the
driven PCs retain only informative shared subspace and reveal the true separation among
subjects.
In chapter 3, we propose two approaches that resolve the issues occurred by an individual
PCA. We hypothesize that several PCA results from compatible data sets have an advantage
to elucidate the common cause of variance throughout data sets regardless of individual
noise and heterogeneity of each study. Focusing on the commonness among studies is the
philosophy of what we are trying to do with MetaPCA by finding the “optimal common
subspace” in multiple studies.
Although some similar ideas have been in the literature, in our knowledge there was
no eﬀort to apply the concept of MetaPCA to genomic researches. Current literatures
regarding to genomic meta analysis are wholly focused on biomarker detection or gene set
enrichment analyses. Here, we have investigated the simultaneous dimension reduction of
multiple microarray studies using MetaPCA, and we show the usefulness of common subspace
in terms of dimension reduction for data visualization and classification.
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As the last aim, in chapter 4 we have investigated methods to integrate transcriptomic
and phenomic data. It is necessary to define phenotypes of disease states to investigate
their underlying molecular mechanisms and develop new treatment strategies, therapeutics,
and biomarkers. Using chronic lung diseases which are commonly thought of as clinically
distinct, we demonstrate a computational approach to“reverse phenotype” patients using
both clinical and gene expression data. We acquired lung tissue, computed tomography, and
clinical data on 474 subjects who were initially given a clinical diagnosis of either intersti-
tial lung disease (ILD) or chronic obstructive pulmonary disease (COPD). We performed
unsupervised clustering on patients with both phenomic and genomic data. We developed
insightful feature visualization tools to explore and interpret the clusters. Pathway analysis
and clinical feature correlation are performed to characterize and annotate the identified in-
termediate phenotypic patients. We showed the convergence/divergence patterns of disease
phenotypes in the integrated clustering by clinical and molecular features. Large number
of patients was in oﬀ-diagonal clusters which represent discordancy between clinical and
molecular phenotypes. This is the first paper that systematically integrate genomic and
phenomic data in ILD and COPD. We identified new clusters of intermediate phenotypic
patients that may lead to improved understanding of these diseases and novel therapeutic
approaches. Approximately 24 million adults in the US are aﬀected by chronic lung diseases
and 119,000 dies each year mostly due to COPD or ILD. Our findings reflect that current
clinical definitions and classification do not account for the large number of patients having
intermediate phenotypes or less common features that are often excluded from clinical trials
and epidemiology reports.
Overall the theme of this thesis is information integration to maximize information gain
and resolve pitfalls in individual or single type of data analysis. We developed sophisti-
cated and objective methodologies in the numerical evaluation of study quality by adopting
statistical inferences and computation approaches. We showed both the power of genomic
meta-analysis and the necessity of proper inclusion/exclusion criteria. Based on the quality
control results, in the second part, we selected a set of quality studies for a meta-analysis,
and we could successfully observe the information gain through our proposed novel genomic
integrative analysis in dimension reduction. One of conclusions in the analysis is that we
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need homogeneous studies to borrow beneficial information from other studies. In the third
part, our innovative integration approach of transcriptomic and phenomic data elucidated
homogeneous clusters of patients who are not defined previously. Our work can be served
as a framework for further studies that seek integrative interpretation of interesting pa-
tients group which may lead to consensus definition of novel subtype of the two chronic lung
diseases.
In chapter 2, integrative quality control criteria are proposed, and application to real data
sets and simulation studies are followed. Chapter 3 focuses on development of MetaPCA
and its application to real data sets. In chapter 4, we present a novel framework to integrate
phenomic or transcriptomic data. Finally, in chapter 5, we discuss overall conclusion of our
work and future direction to extend our methodologies.
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2.0 METAQC: OBJECTIVE QUALITY CONTROL AND
INCLUSION/EXCLUSION CRITERIA OF GENOMIC META-ANALYSIS
Genomic meta-analysis that combines multiple microarray studies have been widely applied
to increase statistical power and to validate results from individual studies. Currently, the
inclusion/exclusion criteria to the analysis mostly depend on ad-hoc expert opinion or na¨ıve
decision by sample size or array platform. To our knowledge, no objective quality assessment
has been developed. In this paper, we propose six quantitative quality control measures, cov-
ering internal homogeneity of co-expression structure among studies (internal quality control,
IQC), external consistency of co-expression pattern with pathway database (external quality
control, EQC), and accuracy and consistency of diﬀerentially expressed gene detection or
enriched pathway identification (accuracy quality control, AQCg and AQCp; consistency
quality control, CQCg and CQCp). Each quality control index is defined as the minus log
transformed p-values from formal hypothesis testing. Principal component analysis biplots
and a standardized mean rank are applied to assist visualization and decision. We applied
the proposed method to four microarray meta-analysis examples: 7 brain cancer studies,
9 prostate cancer studies, 8 idiopathic pulmonary fibrosis studies, and 17 major depressive
disorder studies. The identified problematic studies are scrutinized to identify technical and
biological causes (e.g. sample size, platform or tissue processing) of their bad quality or
irreproducibility to determine exclusion from the final meta-analysis. The results generated
systematic suggestions to exclude problematic studies for genomic meta-analysis of microar-
ray. The method can be extended to meta-analysis applications of genome-wide association
studies or other sequence-based new technologies.
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2.1 INTRODUCTION
Microarray has been an eﬀective and economic technology to monitor gene expression of
tens of thousands genes simultaneously. Since its introduction, it has been used to generate
tremendous amount of data that are accumulated in the public repositories such as NCBI
Gene Expression Omnibus [18], EBI ArrayExpress [76] and Stanford Microarray Database
[95]. Despite the huge amount of data available, the analysis of individual microarray study
often suﬀers from limited statistical power caused by small sample sizes and the results are
inconsistent result with other related studies due to heterogeneous cohorts, data annotation
or preprocessing errors [21, 105, 44, 16].
Meta-analysis has gained popularity in the genomic research in light of its successful
application to traditional epidemiological and medical researches. Many microarray meta-
analysis methods have been proposed to increase statistical power and obtain validated
results across studies. Methods for detecting diﬀerential expression genes include Fisher’s
method [25, 86], Stouﬀer’s method [102], LASSO [30], random eﬀects model [9, 101], Bayesian
methods [49, 108], rank-based methods [6, 38], and others [74, 64]. In addition to DE gene
detection, a statistical framework for microarray pathway meta-analysis was also proposed
[94]. Hong et al. [37] and Campain and Yang [7] compared performance of diﬀerent microar-
ray meta-analysis methods. Ramasamy et al. [84] discussed key issues and a practical guide
for performing microarray meta-analysis. Although the advantages of genomic meta-analysis
are apparent, a quantitative and objective approach to decide the inclusion or exclusion cri-
teria of microarray meta-analysis has not been pursued yet, to our knowledge. Instead, most
literatures depend on subjective expert opinions or ad hoc criteria (e.g. platforms, tissue
types used or number of sample sizes) [87, 35, 113, 68, 97, 17]. Conceptually, including a
bad quality or outlying study in the information integration can greatly dilute information
contained, weaken statistical power or even distort final biological conclusions. To alleviate
such potential pitfalls in meta-analysis [23], it is necessary to develop an objective inclu-
sion/exclusion evaluation tool.
In this paper, we proposed quantitative measures to assess the quality and consistency
of microarray studies for meta-analysis. Specifically, we developed six quality control mea-
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sures (see Table 2 for a brief summary) and utilized principal component analysis (PCA)
biplots and a standardized mean rank (SMR) summary score to assist identification of prob-
lemtic studies. We then applied the proposed methods to four examples, each containing
7 brain cancer, 9 prostate cancer, 8 idiopathic pulmonary fibrosis (IPF) and 17 major de-
pressive disorder (MDD) microarray studies. Impacts and eﬀectiveness of the proposed
inclusioin/exclusion evaluation on the final meta-analysis results were evaluated in the real
examples. Additional simulations were performed to show the robustness and eﬀectiveness
of the proposed method. To our knowledge, this is the first systematic and objective quality
assessment tool developed to decide inclusion/exclusion criteria for genomic meta-analysis.
The QC measures and evaluation are described specifically for microarray meta-analysis in
this paper but potentially can be generalized to genome-wide association studies (GWAS)
or increasingly popular deep sequencing data sets.
2.2 METHODS
To assess the information quality of a microarray data set, we have sought several numerical
measures from diﬀerent perspectives. Overall we propose six quantitative quality control
scores to find a cluster of studies which can be characterized as homogeneous, consistent,
highly influential, and accurate for a further meta-analysis. Table 2 shows the summary of
each quality control criterion.
Before presenting the specific quality control criteria, we first address the general struc-
ture of given data sets. Suppose we are trying to combine the K number of microarray
studies, each study Ek (k = 1...K) is denoted as
Ek = {xkgs}1≤g≤G; 1≤s≤Sk and {yks}1≤s≤Sk
, where {xkgs} represents the expression intensity of gene g and sample s in the study k,
and {yks} denotes the clinical outcome of sample s in the study k, which can be binary,
multi-class, continuous, or censored; G represents the total number of genes when genes are
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matched across studies, and Sk represents the number of samples in the study k. Also we
define a gth gene vector in the kth study as xkg = (xkg1, xkg2, ..., xkgSk).
2.2.1 Internal quality control (IQC) index
In this first criterion, the internal homogeneity of co-expression structure among studies is
evaluated as an internal quality control (IQC) index. The IQC is a comparative measure that
compares pair-wise diﬀerences among studies in an unsupervised manner (without any prior
or external information other than the expression profile data) and the aim is to identify
potential inconsistent or outlier studies from the quantified co-expression dissimilarity. We
apply a concept of the correlation of correlations that was previously reported in the context
of reproducibility analysis of gene co-expression patterns across studies, named as integrative
correlation coeﬃcients [28, 77]. Consider K studies to be combined. For a given study
k, we define ρkij = cor(xki, xkj) as the Pearson correlation coeﬃcient of gene expression
intensities between gene i and gene j in study k. The similarity between two studies m and
n is defined as rmn = spcor ((ρmij; 1 ≤ i ≤ j ≤ Gmn), (ρnij; 1 ≤ i ≤ j ≤ Gmn)), which is the
Spearman’s rank correlation of the pairwise correlation structure between study m and n.
The dissimilarity (or distance) between study m and n is defined as dmn = (1 − rmn)/2.
For a given study k, consider the set of distances from all other studies to the study k
(i.e. D˜∗k = {dkn}1≤n≤K;n￿=K) and the set of all pairwise distance that do not involve study
k (i.e. D˜#k = {dmn}1≤m￿=n≤K;m￿=K,n￿=K). When study k is an outlying study that contains
co-expression structure very diﬀerent from all other studies, the distances in D˜∗k are generally
much greater than those in D˜#k . Consider the two sets of distances follow certain probability
distributions: D˜∗k ∼ F1 and D˜#k ∼ F2. We perform a hypothesis testing based on H0 : F1 =
F2 vs. Ha : F1 = F2 and apply one-sided Wilcoxon rank-sum (a.k.a. Mann-Whitney U) test
[65] to generate a p-value, PIQC(k). Figure 1a shows an example that study 1 has a very
diﬀerent co-expression structure from other three studies and we will compare (d12, d13, d14)
and (d23, d24, d34) by Wilcoxon rank-sum test to obtain a small p-value for study 1.
The hypothesis setting gives small p-value when study k is an outlying study. We apply
a reverse transformation g(p) such that large p-value correspond to an outlying study. The
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transformation will make the minus-log transformation below a quality score and consistent
to the other QC measures to be introduced later. To keep the 0.05 statistical significance
threshold invariant in the transformation, we define g as g(p) = 1 − FD2(F−1D1 (p)), where
D1 ∼ N (z.95, 1) and D2 ∼ N (−z.95, 1). For example, g(0.05)=0.05, g(0.5)=0.0005 and
g(0.01)=0.17. Figure 1b shows a plot of the transformation. Finally, the IQC measure of
study k is defined as IQC(k) = −log10 g (PIQC(k)). We will use log base 10 for all QC
measures in this paper. Large IQC indicates that the study has homogeneous co-expression
structure with other studies and is considered good quality to be included for meta-analysis.
0 1 2 3 4
0
1
2
3
4
E4E3
E2
E1
d34
d23 d24
d14
d13
d12
(a) Concept of IQC
0.05 0.10 0.15 0.20 0.25
0.
00
0.
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Figure 1: Internal Quality Control. (a) Three points in the lower left represent homo-
geneous studies, and a point in the upper right is a heterogeneous study which has larger
pair-wise distance to others. (b) X and Y axis are p-values before and after applying trans-
formation g; as the result, smaller p-values mean stronger homogeneity.
2.2.2 External quality control (EQC) index
Compared to the unsupervised approach achieved in IQC, we develop a supervised quanti-
tative criterion, named as external quality control (EQC) criterion. External knowledge of
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pathways (i.e. functional or co-regulated gene sets) obtained from established databases (e.g.
KEGG, GO, Biocarta and MSigDB) is applied to evaluate its consistency with a given study
and subsequently to determine the study quality. We use similar pairwise gene correlation
structure concept used in IQC and define an association measure between study k and a
given pathway (gene set) w by
tk = tk ({ρkij}1≤i,j≤Gk ;w)
=
￿ ￿
j>i;i,j∈w
|ρkij |l
|w|·(|w|−1)/2
￿1/l￿￿ ￿
1≤i<j≤Gk
|ρkij |l
|Gk|·(|Gk|−1)/2
￿1/l
, where ρkij is the Pearson correlation of gene i and gene j in study k as defined in IQC,
the numerator is the l-norm average of absolute pairwise correlation in pathway w, the
denominator is the corresponding l-norm average in the background genome Gk, and |w|
and |Gk| are the number of genes in the pathway w and study k. If pathway w is relevant
to disease status or experimental perturbation, we expect that the l-norm average among
the pathway in the numerator will be much larger than that among genome background in
the denominator and tk will be significantly greater than 1. In this association measure,
we disregard the sign of correlation coeﬃcients and use l-norm to inflate diﬀerential impact
of high and low correlations in the measure. We will use l = 2 throughout this paper
to down-weight medium to low correlation coeﬃcients and gives higher relative weight to
large correlation coeﬃcients (e.g. 0.82=0.64 and 0.32=0.09). We set up hypothesis testing
H0 : tk = 1 vs. Ha : tk > 1 and apply Monte-Carlo permutation analysis to obtain the
empirical null distribution of the test statistic tk [10, 71]. Specifically, we randomly sample
fromGk a random pathway w(b) of equal size (i.e. |w(b)| = |w|) in the bth simulation, calculate
the corresponding t(b)k and repeat for B times (b=1,...,B). The resulting p-value of the test is
calculated as PEQC(k;w) = (
B￿
b=1
I(t(b)k > tk)+1)/(B+1), where I(·) is an indicator function.
Here, we adopt a conservative procedure to add 1 to both denominator and numerator in
p-value calculation, considering the observed statistics is one of the simulated cases [71].
The EQC measure is then defined as EQC(k;w) = −log10 PEQC(k;w). Similar to IQC,
large EQC(k;w) indicates that the study has significantly higher association with pathway
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w in terms of gene pairwise correlation structure and is thus considered good quality to be
included for meta-analysis.
We further extend the EQC measure for multiple pathways. Consider among M pathways
W = {wm, 1 ≤ m ≤ M} available, a significant portion of them have high association
measure with study k. We define a Fisher’s score [25] by Sk = −2
M￿
m=1
logPEQC(k;wm). If
the pathways are independent, the S score follows a chi-squared distribution with degree of
freedom 2M. However, since the biological pathways always have hierarchical structure and
high overlapping, we perform permutation analysis for B times to obtain simulated S(b)k . The
resulting p-values is calculated as PEQC(k;w) = (
B￿
b=1
I(S(b)k > Sk)+1)/(B+1), and the EQC
measure is similarly defined: EQC(k;W ) = −log10PEQC(k;W ).
Comparing IQC and EQC, we note that EQC relies on a good selection of pathway set
W and the evaluation of one study is independent from other studies. IQC, on the other
hand, is a relative measure that depends on other studies under consideration but does not
require external biological information.
2.2.3 Accuracy quality control (AQCg and AQCp) and consistency quality con-
trol (CQCg and CQCp) index
In the third and fourth criteria, we propose an accuracy quality control (AQC) and a consis-
tency quality control (CQC) criteria that are aimed to quantify the reproducibility (accuracy
or consistency) of diﬀerentially expressed genes (or pathways) detected in an individual study
compared to those detected by meta-analysis. For AQCg for study k, the identified DE gene
list from meta-analysis excluding study k (using Fisher’s method under FDR=r%) is served
as a gold standard. The DE gene list detected by study k (using Student’s t-test with
Benjamini-Hochberg procedure under FDR=r%) is then compared to the gold standard to
generate a 2×2 table and calculate the sensitivity, specificity and Youden’s index [121] (de-
fined as sensitivity+specificity-1). One-sided Fisher’s exact test can be used to determine the
association (reproducibility) of DE gene list identified by meta-analysis and that identified
by study k (H0: the two gene lists have no association. vs. Ha: the two gene lists have
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association). The p-value for study k is calculated from hypergeometric distribution:
PAQCg(k) =
min(T (k),T (−k))￿
t=tk
￿
T (k)
t
￿￿Gk − T (k)
T (−k) − t
￿￿
Gk
T (−k)
￿
, where G is the total number of genes, T (k) is the number of DE genes detected by study k,
T (−k) is the number of DE genes detected by meta-analysis excluding study k and tk is the
number of DE genes detected both by study k and by meta-analysis excluding study k (see
the 2×2 table in Table 1). The AQCg score is defined as AQCg(k; r) = −log PAQCg(k; r).
We use FDR threshold r = 5 but can relax it to 10 or 20 when the data have weak signal.
Large AQCg measure for a given study k indicates that DE genes produced by study k
is reproducible compared to DE genes detected by meta-analysis excluding study k. We
extend AQCg to AQCp where DE genes in the AQCg definition are replaced by enriched
pathways. The pathway enrichment can be obtained by simple Fisher’s exact test under
certain DE gene threshold or other gene set analysis methods (e.g. GSEA [103] or GSA
[19]). In this paper, we used simple Kolmogorov-Smirnov test under FDR=5% threshold to
obtain enriched pathways.
In contrast to evaluating DE gene lists from a hard threshold in AQCg, we also apply
an alternative of consistency quality control (CQC) measure by evaluating the consistency
of diﬀerential expression ranking from single study analysis and meta-analysis. Specifically,
ranks of diﬀerential expression evidence of study k is first calculated by Student’s t-test
and defined as R(k)g for gene g and study k. From meta-analysis (using Fisher’s method)
excluding study k, the ranks of diﬀerential expression evidences are denoted as R(−k)g . The
Spearman rank correlation between two rank vectors is defined as
ρk = spcor
￿
(R(k)g ; 1 ≤ g ≤ Gk), (R(−k)g ; 1 ≤ g ≤ Gk)
￿
= 1 − 6 ·
Gk￿
g=1
(R(k)g −R(−k)g )2
Gk(G2k−1)
. To test H0 :
ρk = 0 vs. Ha : ρk > 0, we can approximate that t = ρk ·
￿
Gk−2
1−ρ2k
follows a Student’s t
distribution with Gk− 2 degree of freedom under null hypothesis [52]. The resulting p-value
is calculated as PCQCg(k) = 1− FGk−2(ρk ·
￿
Gk−2
1−ρ2k
), where FGk−2 represents the cumulative
distribution function (cdf) of Student’s t-distribution with Gk − 2 degree of freedom. The
CQCg score is defined as CQCg(k) = −log10PCQCg(k). Having a large CQCg measure for a
given study k indicates that DE evidence produced by study k is relatively consistent with
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DE evidence generated by meta-analysis excluding study k. We can also extend CQCg to
CQCp where DE evidence and gene ranking in the CQCg definition are replaced by enriched
pathways.
Table 1: Contingency table for AQC inference
TRUE FALSE TRUTH
TRUE tk T (−k) − tk T (−k)
FALSE T k − tk F (−k) − T k + tk F (−k)
Observed T k F k Gk or Wk
Table 2: Summary of Six Quality Control Scores
Types Evaluation External Pathway Clinical Outcome
Criteria Knowledge Needed? Needed?
IQC Homogeneity of co-expression No No
EQC Consistency of co-expression Yes No
CQCg Consistency of gene ranking No Yes
CQCp Consistency of pathway ranking Yes Yes
AQCg Accuracy of detected biomarkers No Yes
AQCp Accuracy of detected pathways Yes Yes
2.2.4 Visualizatioin and summarization for decision
We apply principal component analysis biplots [46] to assist the visualization and decision for
inclusion or exclusion of studies in meta-analysis. Each microarray study is projected from
high dimensional QC measures to a two dimensional PC subspace. The direction of each
quality control measure is juxtaposed on top of the two-dimensional subspace using arrows.
Specifically, the coordinates of each quality criterion are determined by its correlation to two
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driven PCs. The origin of the biplot is taken as the statistical threshold with Bonferroni
correction (i.e. projected from log10(0.05/#studies) in each of the QC measure dimensions),
suggesting that studies located in the opposite area of arrows are candidate outlier studies.
The scale of each QC measure is standardized before PCA to avoid dominance of a particular
QC measure due to scale problem. In addition to biplot visualization, we also define a
quantitative summary score by calculating the ranks of each QC measure among all studies
and then compute the standardized mean rank (SMR) of each study: (mean rank of all QC
meausres)/(# of studies). By definition, 0 < SMR ≤ 1. Since CQCg and AQCg are usually
highly correlated in our examples and CQCp and CQCp are highly correlated, we combine
each pair of them by average into new QC measures, named as consistency and accuracy
quality control (CAQCg and CAQCp) measures.
Note that our visualization and summarization tools are not meant for an automated
recommendation. In the examples we explored, there are three categories in QC results:
bad quality for definite exclusion, good quality for definite inclusion and borderline cases.
Definite exclusion cases are often on the opposite side of arrows in the PCA biplots and have
small QC ranks (and thus small SMR score). These studies are strongly suggested to be
excluded from meta-analysis. On the other hand, definite inclusion cases are on the same
side of arrows in the PCA biplots and have large rank scores. They are clearly good quality
studies that should be included. Borderline studies happen to be in between the two extreme
cases. Although an automated quantitative decision is desirable, it is often not practical.
One should seek additionial qualitative assessment for the causes of bad quality, no matter
for definite bad studies or borderline studies.
2.2.5 Application, evaluation and simulation in real datasets
We have evaluated our proposed method to four examples: brain cancer (7 studies), prostate
cancer (9 studies), Idiopathic Pulmonary Fibrosis (IPF) (8 studies), and major depressive
disorder (MDD) (17 studies). Summary of these studies is listed in tables 3 - 6. The most
microarray data sets were collected from public repositories such as NCBI Gene Expression
Omnibus [18] and EBI ArrayExpress [76], or web pages directed in the original papers.
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Several non published data sets were obtained from the labs of Dr. Kaminski and Dr. Sibille.
Most data sets are already normalized by original authors. When raw data are available,
RMA [45] was applied for preprocessing. To obtain a robust result, we have applied a
gene filtering in each study level, which removes 40% of non-expressed genes based on the
expression intensity and 40% of non-informative genes based on variance. Gene matching
across studies is done by matching oﬃcial gene symbols using Bioconductor [29] packages.
When multiple probes match to one gene symbol, the probeset which has the largest IQR is
selected.
In EQC criterion, external pathways are needed for calculating EQC measures. We only
considered pathways that have at least 5 genes in each study. Conceptually, using pathways
relevant to the disease or experimental perturbation will generate better EQC evaluation.
For cancer studies, we chose to use GSEA Biocarta v3.0 pathways [103] since the pathways
are cancer specific. A total of 217 Biocarta pathways were used in the brain cancer example.
For prostate cancer studies, the overall data quality and information seemed to be weaker
and we chose only the top 50 pathways among the 217 pathways for better performance
(top pathways were identified by combined p-values using Fisher’s method). For MDD stud-
ies, 99 pathways were selected from all GSEA MSigDB v3.0 by the keyword search using a
list of relevant terms provided by Dr. Sibille: GABA, INSULIN, DIABETES, IMMUNE,
THYROID, ESTROGEN, DEPRESSION, AGING, ALZHEIMERS, PARKINSONS, and
HUNTINGTONS. For IPF studies, we have chosen top 50 pathways out of all 6769 number
of GSEA MSigDB v3.0 pathways in terms of the EQC measure. For AQCp and CQCp
measures, pathway database is also needed to generate enriched pathways before evaluation.
We use all MSigDB c2 v3.0 pathways for both AQCp and CQCp in all four examples.
We performed 100,000 simulations in the permutation analysis of Fisher scores in EQC
measure and thus the largest range of EQC measure is limited to 5 (that corresponds to
p=1E-5). For AQC measures, we applied two-sample Student’s t-test and Kolmogorov-
Smirnov test for AQCg and AQCp, respectively. All p-values were adjusted by Benjamini-
Hochberg procedure [3] to control FDR at the level of 0.05. Fisher’s method (sum of minus
log-transformed p-values) was used for meta-analysis in both AQC and CQC evaluation
when performingn meta-analysis of all studies except for the study k. In AQC measures,
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weak signal examples may generate only few DE genes or pathways that makes the AQC
measure invalid or unstable. We chose a liberal cutoﬀ (unadjusted p < 0.05) to prevent each
lower score from having zero value because of weak signal.
To assess the validaty and performance of our proposed method, we performed down-
stream analysis to assess its impact on DE gene and pathway detection and performed
simulation to assess the accuracy of detecting problematic studies. The results are reported
in the following section. All implementation was written by R statistical language [83]. An
R package, “MetaQC” is publicly available online at CRAN (http://cran.r-project.org/)
2.3 RESULTS
2.3.1 Quality assessment in four examples
Table 3 - 6 lists summary information of studies in the four examples. For brain cancer
example, we have obtained 7 brain cancer studies comparing Anaplastic Astrocytoma (AA)
and Glioblastoma multiforme (GBM) samples (Table 3). Dreyfuss et al. [17] have combined
four studies for meta-analysis of which three are used in this analysis. Figure 2A shows the
PCA biplot of the result and Table 7 shows the detailed QC measures and SMR score. The
first two PCs in Figure 2A explains about 92% of total variance, and all scores are highly
positively correlated with the first PC. The scores marked with asterisks in Table 7 indicate
non-statistical significance (p > 0.05/# of studies), which means the specified study might
have an adverse eﬀect on meta-analysis based on the QC measure. The Yamanaka study is
clearly below statistical threshold and has low values in all measures; it is a definite exclusion
case that should be excluded from the meta-analysis. On the other hand, the top 5 studies in
Table 7 performed very well for all criteria, indicating that they are definite inclusion cases
for meta-analysis. The Paugh study (study 6 in Figure 2A), is however a borderline case.
The QC measures were mostly low and just passed the statistical significance. Interestingly,
when scrutinizing the causes of poor quality of Yamanaka and Paugh studies, Yamanaka
uses a diﬀerent platform and both studies are of smaller sample size.
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In the second example, we applied proposed QC assessment to 9 prostate cancer studies
comparing normal and primary cancer patients. The data details are summarized in Table
4. QC results are shown in Figure 2B and Table 8. Compared to brain cancer studies, we
found that prostate cancer studies were mostly performed in earlier years with older array
platforms. Although the first two PC also capture high percentage of variance (93%), the
studies more scattered around and even good studies had quite diﬀerent performance by dif-
ferent QC criteria. For example, Varambally and Wallace had better score on IQC and EQC
but not CQC and AQC while Welsh, Lapointe, and Singh, had better performance in CQC
and AQC but not IQC and EQC. Yu had performed the best in all criteria. In considering
sample size, array platform and QC measures, we suggest to exclude the bottom 3 studies:
Nanni, Tomlins, and Dhanasekaran from meta-analysis and mark Singh as a borderline case.
The worse performance of prostate cancer studies shown here reflects the fact that prostate
cancer is a heterogeneous cancer [89].
As a third example, we evaluated 8 Idiopathic Pulmonary Fibrosis (IPF) studies which
identify signature genes of IPF patients compared to normal. IPF is one of the most lethal
chronic lung disease, and its mean survival is only 3-5 years regardless of treatment [54].
Table 5 shows data summary, Figure 2C demonstrates the PCA biplot and Table 9 lists the
details of QC scores. Interestingly, although these 8 data sets are mostly from very diﬀerent
microarray platforms, at least five of them performed very well, indicating good quality for
meta-analysis. Of the three worst QC studies, Emblom utilized a cDNA array platform
which might caused the worst performance. Yuga and Larsson both have small sample size
(n=7 for Yuga and n=12 for Larsson) which might be the reasons of low QC scores. The two
top studies, KangA and KangB, are unpublished data from Dr. Kaminskis lab with large
well-characterized cohorts.
In our final example, we apply QC evaluation to 17 Major Depressive Disorder (MDD)
studies that compare normal and MDD patients. These 17 studies are obtained from post-
mortem brain tissues of various brain regions and are considered very weak signal, small
sample size and heterogeneous data sets. The details of each data set is in Table 6. The
QC results are shown in Figure 2D and Table 10. In Figure 2D, noticeably many studies
scattered near the origin because of weak signal of most studies. From Table 10, the top
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3-5 studies are clear definite inclusion studies and the bottom five studies are definite exclu-
sion studies. Other studies are borderline cases somewhat in the middle. Most CQCg and
AQCg scores are significantly lower than other examples since each individual MDD study
is weak signal and the DE gene and pathway detections are relatively unstable. We note
that the 7 out 9 bottom studies were all from Stanley Foundation Tissue Bank, which has
been suspected to have worse quality from problematic tissue collection and processing.
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Table 3: 7 Brain Cancer Studies (AA vs. GBM)
Arthor Year Platform Sample Size Source
Freije[27] 2004 HG-U133A,B 85 GSE4412
Phillips[80] 2006 HG-U133A,B 100 GSE4271
Sun[104] 2006 HG-U133 Plus 2 100 GSE4290
Yamanaka[118] 2006 Agilent 29 GSE4381
Petalidis[79] 2008 HG-U133A 58 GSE1993
Gravendeel[34] 2009 HG-U133 Plus 2 175 GSE16011
Paugh[78] 2010 HG-U133 Plus 2 42 GSE19578
Table 4: 9 Prostate Cancer Studies (Normal vs. Primary)
Arthor Year Platform Sample Size Source
Dhanasekaran[15] 2001 cDNA 32 www.pathology.med.umich.edu
Welsh[112] 2001 HG-U95A 34 public.gnf.org/cancer/prostate/
Singh[96] 2002 HG-U95Av2 102 www.broad.mit.edu/
Lapointe[58] 2004 cDNA 103 GSE3933
Yu[122] 2004 HG-U95Av2 146 GSE6919
Varambally[109] 2005 HG-U133 Plus 2 13 GSE3325
Nanni[69] 2006 HG-U133A 30 GSE3868
Tomlins[107] 2006 cDNA 57 GSE6099
Wallace[111] 2008 HG-U133A2 89 GSE6956
Table 5: 8 IPF Studies (Normal vs. IPF)
Arthor Year Platform Sample Size Source
Pardo[75] 2005 Codelink 24 GSE2052
Yang[119] 2007 Agilent 43K 29 GSE5774
Larsson[59] 2008 HG-U133 Plus 2 12 GSE11196
Vuga[110] 2009 Codelink 7 GSE10921
Konishi[55] 2009 Agilent 4x44K 38 GSE10667
Emblom[22] 2010 cDNA 58 GSE17978
KangA 2011 Agilent 4x44K 63 -
KangB 2011 Agilent 8x60K 96 -
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Table 6: 17 MDD Studies (Normal vs. MDD)
Data Name Year Platform Sample Size Source
MD1 AMY 2009 HG-U133 Plus 2 28 Dr. Sibille
MD3 AMY 2009 HumanHT-12 42 Dr. Sibille
MD1 ACC 2009 HG-U133 Plus 2 32 Dr. Sibille
MD3 ACC 2009 HumanHT-12 44 Dr. Sibille
MD2 ACC M 2010 HG-U133 Plus 2 18 Dr. Sibille
MD2 ACC F 2010 HG-U133 Plus 2 26 Dr. Sibille
MD2 DLPFC M 2010 HG-U133 Plus 2 28 Dr. Sibille
MD2 DLPFC F 2010 HG-U133 Plus 2 32 Dr. Sibille
NY DLPFC M 2004 HG-U133A 26 Dr. Sibille
NY oFC M 2004 HG-U133A 24 Dr. Sibille
Feinberg - HG-U95Av2 27 www.stanleygenomics.org
KatoB 2004 HG-U95Av2 26 www.stanleygenomics.org
Kemether - HG-U133p 24 www.stanleygenomics.org
AlartC - HG-U133A 22 www.stanleygenomics.org
SklarA - HG-U95Av2 23 www.stanleygenomics.org
SklarB - HG-U95Av2 23 www.stanleygenomics.org
Sokolov - HG-U95A 26 www.stanleygenomics.org
21
Figure 2: Integrative quality control. Each circled number represents the overall rank of
a study. Smaller number corresponds to higher quality study. A) 7 brain cancer studies: the
7th ranked studies, Yamanaka, looks definite outlier study; the 6th study, Paugh, is in the
borderline; the top five studies look solid. B) 9 prostate cancer studies: the top five studies
look good, the 6th ranked study is in the borderline, and the bottom three studies, Nanni,
Tomlins, and Dhanasekaran, are outliers. C) 8 IPF studies: the top four studies looks good;
the three studies ranked between 5 to 7 are in the borderline; the 8th ranked study, Emblom,
is a definite outlier. D) 17 MDD studies: the bottom four studies look outliers; the top ten
looks fine, and between 11th and 13th ranked studies look to be in borderline.
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Table 7: Brain Cancer Study - Quality Control Scores
# Study IQC EQC CQCg CQCp AQCg AQCp Rank
1 Sun 4.96 5.00 307.65 251.33 152.83 108.37 1.88
2 Freije 5.42 5.00 239.31 158.73 118.06 81.62 2.62
3 Phillips 4.52 5.00 242.36 146.71 106.59 69.19 3.62
4 Petalidis 4.11 3.16 274.25 171.48 111.27 101.10 3.75
5 Gravendeel 6.64 4.70 98.37 107.06 47.67 63.89 4.00
6 Paugh 1.51* 5.00 5.00 3.60 2.31 9.84 5.12
7 Yamanaka 0.10* 0.78* 1.69* 2.26 1.58* 0.71* 7.00
Table 8: Prostate Cancer Study - Quality Control Scores
# Study IQC EQC CQCg CQCp AQCg AQCp Rank
1 Yu 7.74 3.23 52.43 64.14 19.95 38.30 2.25
2 Welsh 5.04 2.12* 68.59 101.31 26.46 54.66 2.50
3 Lapointe 4.06 2.28 26.36 59.42 7.00 33.90 3.75
4 Varambally 4.68 4.70 15.38 21.15 4.18 13.21 3.88
5 Wallace 7.95 4.22 0.00* 28.70 0.00* 2.13* 4.75
6 Singh 2.14* 2.05* 19.60 28.74 4.61 24.17 5.25
7 Nanni 1.92* 1.92* 2.22* 6.01 2.00* 13.61 6.75
8 Tomlins 2.67 0.52* 3.76 3.65 1.19* 6.12 7.38
9 Dhanasekaran 0.01* 0.63* 0.01* 0.23* 0.04* 0.10* 8.50
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Table 9: IPF Study - Quality Control Scores
# Study IQC EQC CQCg CQCp AQCg AQCp Rank
1 KangA 6.64 5.00 307.65 146.87 96.71 90.88 1.88
2 KangB 5.57 5.00 273.67 114.30 84.37 69.74 2.62
3 Konishi 6.89 5.00 58.19 42.70 25.50 57.20 2.75
4 Yang 4.34 5.00 41.70 56.35 14.20 29.43 3.88
5 Pardo 4.07 2.08* 25.14 38.84 20.60 25.05 5.38
6 Vuga 2.28 5.00 1.37* 26.25 1.77* 18.01 5.38
7 Larsson 1.79* 5.00 0.59* 1.88* 0.52* 3.21 6.25
8 Emblom 0.03* 1.12* 0.83* 0.57* 0.43* 1.98* 7.88
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Table 10: Major Depressive Disorder Study - Quality Control Scores
# Data Name IQC EQC CQCg CQCp AQCg AQCp Rank
1 MD2 ACC F1 9.80 5.00 19.22 40.01 6.17 27.47 3.75
2 MD2 DLPFC M1 3.22 5.00 56.70 41.02 9.37 33.27 4.38
3 MD2 ACC M1 3.76 3.05 24.59 33.78 3.80 17.16 6.62
4 MD1 ACC1 3.41 5.00 10.59 19.28 0.39* 10.21 6.62
5 MD2 DLPFC F1 3.05 1.12* 52.05 62.94 14.32 46.79 7.00
6 NY oFC M1 11.56 3.74 0.12* 18.09 0.4* 13.32 7.25
7 NY DLPFC M1 4.05 5.00 1.63* 14.82 0.3* 6.61 7.88
8 MD3 AMY1 0.96* 5.00 3.23 12.03 1.54* 7.05 8.50
9 KatoB2 11.54 5.00 0* 1.46* 0.45* 2* 8.62
10 Kemether2 8.01 1.91* 12.21 8.92 9.79 1.63* 8.75
11 MD3 ACC1 1.37* 4.70 8.70 15.65 1.8* 4.06 9.38
12 MD1 AMY1 3.09 2.97 1.49* 17.14 0.39* 16.76 9.62
13 SklarB2 0.73* 5.00 0* 9.71 0* 8.80 10.75
14 Sokolov2 4.07 0.3* 0.46* 1.4* 0.6* 6.85 10.75
15 Feinberg2 0.35* 5.00 0.32* 2.41* 0.17* 0.77* 13.12
16 SklarA2 1.2* 1.93* 0* 1.01* 0* 2.41* 14.75
17 AltarC2 0.69* 0.08* 0* 15.95 0* 0.91* 15.25
1 Data from our collaborator, Dr. Etienne Sibille.
2 Data from Stanley Foundation, suspected worse quality in the tissue collection and
processing
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2.3.2 Impacts on DE gene and pathway detection
To evaluate the ultimate biological impact of our MetaQC method, we investigated the
marginal impact of a meta-analysis on DE gene and enriched pathway detection. We hy-
pothesized that including an additional informative study in a meta-analysis would provide
increased statistical power to detect more DE genes and enriched pathways. Figure 3A and
4A show the number of DE genes and enriched pathways detected under FDR=0.5%, re-
spectively, when 7 brain cancer studies were added sequentially in the meta-analyses in the
order of SMR score of MetaQC. Interestingly, the number of detected DE genes and pathways
dropped clearly when including the two suspect problematics studies: Paugh and Yamanaka.
The result supported the recommendation provided by MetaQC. This simple incremental
analysis also argues the necessity of adequate inclusion/exclusion criteria in meta-analysis.
The results for prostate cancer (Figure 3B and 4B) and IPF examples (Figure 3C and 4C)
demonstrated more complex situation than in brain cancer. The number of DE genes under
FDR=0.1% generally increased as more studies were added while the number of detected
pathways decreased when the 5th and the 6th studies were added in prostate cancer and IPF,
respectively. In Supplement Figure 2B, we found that Wallace, Singh and Tomlins generally
have stronger DE evidence than other studies. The increased number of detected DE genes
in Figure 3B might have been caused by this bias although the pathway result in Figure
4B did not show increased finding. The prostate cancer example demonstrated a case that
pure AQCg or CQCg method focusing on commonality of DE gene detection is not eﬀective
enough when studies are highly heterogeneous. In the IPF example, similar observation can
be found. Inclusion of Emblom greatly increased the number of DE genes (Figure 3C) but
decreased the number of detected pathways (Figure 4C). This may also be due to the larger
number of DE genes detected by Emblom (Supplement Figure 2C).
Figure 3D and 4D shows the result of the MDD examples. In contrast to previous ex-
amples, MDD studies have very weak overall signals, so we applied very liberal DE gene
detection criterion which is unadjusted p-value=1%. However, in terms of pathway identifi-
cation, we could get a similar number of enriched pathways with usual FDR=5% threshold.
In spite of its liberal threshold, the number of DE genes is smaller than other examples.
26
Also the number of increased DE genes as more studies included is less than others except
Kemether and AltarC which made DE genes increased significantly than its previous step.
However, as we notice from previous two examples, these two studies are not considered as
quality studies because their inclusion caused significant drop in the number of identified
pathways in the figure 4D. Again, supplement figure 2D shows the large number of DE genes
in both studies compared to others.
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Figure 3: Marginal impacts on DE genes detection. X-axis represents each study
included cumulatively to a series of meta-analyses. The order of addition follows the quality
rank in the table 7 - 10. Y-axis represents the number of DE genes. A) The example of 7
brain cancer studies to investigate the marginal impact of including one additional study.
FDR 0.005 was used for DE genes detection. B) The example of 9 prostate cancer studies.
The number of DE genes in y-axis are detected with FDR 0.001. C) The example of 8 IPF
cancer studies. FDR 0.001 was used for DE genes detection. D) The example of 17 MDD
studies. The number of DE genes in y-axis are detected with liberal p-value 0.01.
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Figure 4: Marginal impacts on enriched pathways detection. X-axis represents each
study included cumulatively to a series of meta-analyses. The order of addition follows the
quality rank in the table 7 - 10. Y-axis represents the number of enriched pathways identified
by FDR 0.05. A) The example of 7 brain cancer studies to investigate the marginal impact
of including one additional study. B) The example of 9 prostate cancer studies. C) The
example of 8 IPF cancer studies. D) The example of 17 MDD studies.
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Figure 5: P-value distribution of each example studies. X-axis represents studies which
are ordered by the quality rank in the table 7 - 10. Y-axis represents -log10 transformed p-
value of each gene. A) In 5 brain cancer studies, top 5 studies have comparable distribution
of p-values, and the worst two studies had relatively weak signals. B) In 9 prostate cancer
studies, the overall proportion of significant p-value in Wallace, Singh, and Tomlins was
higher than others. C) In 8 IPF studies, the overall proportion of significant p-value in
Emblom was higher than others, though it had the worst quality. D) In 17 MDD studies,
the overall proportion of significant p-value in Kemether and AltarC was much higher than
others.
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2.3.3 Simulations
To further validate the QC result of our proposed method, we investigated a simple yet
insightful simulation scheme. For example, seven brain cancer studies were fixed for MetaQC
evaluation. In each simulation, an additional prostate cancer study is added as a known
outlier. The simulations were repeated through all prostate cancer studies and the changes
of SMR scores were recorded and compared. In Figure 5A, the 1-SMR scores of seven
brain cancer studies were plotted in the first columns (labelled as “NA”). In the following
nine simulations, a prostate cancer studies was added to the seven brain cancer studies and
the 1-SMR scores were recalculated. The added outlier study was plotted by an asterisk
symbol. The result shows that the added prostate cancer studies always generated small 1-
SMR score similar to Yamanaka study and were always detected as a definite exclusion case.
The result also demonstrated the eﬀectiveness and robustness of our proposed method to
perform QC assessment and screen out outlier studies. Moreover, the addition of a random
irrelevant study as the “null” study provides a more objective and practical threshold to
decide the exclusion of studies. In this context, the decision in brain studies seems evident
that Yamanaka should be excluded. For the second simulation in Figure 5B, a brain cancer
was added as an outlier study to nine prostate cancer studies in each simulation. The results
showed that the added brain cancer study had 1-SMR scores better than Nanni, Tomlins
and Dhanasekaran. Since brain cancer and prostate cancer share some commonalities as two
types of cancers, the added brain cancer studies can serve as a baseline negative control to
argue exclusion of the three bottom studies. In Figure 5C, we further added brain cancer
studies as outliers into the 8 IPF studies. The result showed similar pattern that argues
to exclude Embolm and Larsson studies. Figure 5D shows the result that one of 7 brain
studies are added to 17 MDD studies sequentially. It looks the top 7 studies have the best
quality, and the bottom 5 studies have the worst quality, and the middle 5 studies are in the
borderline.
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Figure 6: Simulation study showing the eﬀect of adding an irrelevant study. Y-
axis represents 1 - standardized mean rank (SMR); high quality studies should have greater
values. X-axis represents the addition of a totally irrelevant study to one of current four
examples. A set of irrelevant studies were obtained from one of the other three examples.
The order of inclusion was based on the quality rank in the table 7 - 10, so high quality
irrelevant studies have smaller x values. NA represents the original quality result without
an irrelevant study which is the same result as table 7 - 10. A black asterisk represents the
1-SMR of the added irrelevant study. Studies under the asterisk should be outliers. A) 7
brain cancer studies. B) 9 prostate cancer studies. C) 8 IPF studies. D) 17 MDD studies.
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2.4 CONCLUSIONS AND DISCUSSIONS
We have proposed 6 quantitative inclusion/exclusion criteria which measures the quality of
studies. The goal of our methods is to find a group of homogeneous studies for the better
result in a meta-analysis. As we can see in the example of prostate cancer studies, many
of them are very heterogeneous. Especially, the striking opposite relationship between the
sharp increase in the number of DE genes in the figure 3 and the sharp decrease in the
number of enriched pathways in the figure 4 suggests that the all inclusive study selection
strategy may lead a very diﬀerent conclusion in the same type of meta-analysis. In contrast,
as we can find in the simulation results, our proposed method incorporated various aspects
of quality assessment criteria so that it can screen out outlier studies in an eﬀective and
robust way and eventually lead to consistent results between meta-analyses.
Although our approaches are not aimed to give a fully automated decision threshold, we
showed that a PCA visualization tool and a simple simulation procedure could be served
as complementary tools to find a reasonable decision boundary without considering any
qualitative information. When it is possible to obtain any reasonable domain knowledge,
the qualitative information would be very useful in the case that when the decision boundary
is very complex as we saw in the MDD example.
Lastly, we observed the importance of homogeneity of studies in a meta-analysis in various
analysis including DE gene detection and enriched pathway identification. Especially, our
newly developed MetaPCA methods showed the significant increase of prediction accuracy
using the top 5 brain cancer studies; however, the eﬀect in top 5 prostate studies was not
significant as the brain studies suggesting that the amount of homogeneity among considered
studies are the barometer of the success of a meta-analysis.
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3.0 METAPCA : META-ANALYSIS IN THE DIMENSION REDUCTION
OF GENOMIC DATA
(This paper is in preparation to submit to Annals of Applied Statistics)
Principal Component Analysis (PCA) enables us to explore high dimensional genomic
data through projection to a low-dimensional space. As an exploratory tool to visualize
subjects in 2 or 3 dimensional subspace while minimizing information loss, PCA is one of
the most popular multivariate analysis techniques. In this paper, we consider simultaneous
dimension reduction using PCA when multiple studies are combined. Although similar
concepts of common principal components analysis exist, the advantage of such a practice in
the meta-analysis context has not been studied. We propose two basic ideas to find a common
PC subspace by eigenvalue maximization approach and angle minimization approach, and
we extend the concept to incorporate Robust PCA and Sparse PCA in the meta-analysis
framework. We evaluated the advantages and limitations of our methodology in the context
of dimension reduction for data visualization and supervised machine learning using five
examples of real microarray data, we show the information gain obtained by adopting our
proposed procedure. We also suggest that for the successful meta-analysis, homogeneous
data selection procedure is necessary.
3.1 INTRODUCTION
The Principal Component Analysis (PCA) is one of the most popular techniques that enable
us to explore high dimensional data through projection to a low-dimensional space. Each
Principal Component (PC) is orderly derived to be a linear combination of original features
34
in that it explains as much of the variance (information) as possible. The first PC is chosen
to have the largest variance, and the next PCs are sequentially derived to have the largest
variance in the orthogonal subspace of selected PCs [46].
One of the many applications of PCA is to visualize high dimensional subjects in two or
three dimensional PC subspace. The derived subspace is the optimal choice to represent as
much information (variance) as possible in such a reduced dimension, i.e. it minimizes the
sum of squares of the projection errors. Another possible application of PCA is to utilize
PCs as an input for other statistical methodologies such as regression analysis or various
multivariate techniques [46, 39, 53]. Two main advantages of PC based approaches are to
overcome the multicollinearity problem which occurs when highly correlated variables are
included together in an analysis and to alleviate the curse of dimensionality which numerous
multivariate methods are suﬀered from [4, 2].
In many cases, PCA has been very successful and gives a concise presentation of overall
data structure. Particularly, when PCA is applied to microarray data, it is hoped that the
chosen PCs elucidate the informative low dimensional manifold such as interesting patterns
or clusters of subject or genes [85, 92, 63, 11, 120]. However, microarray data are often noisy,
and PCA is sensitive to outliers; often times it fails to get an eﬀective representation in the
reduced dimension. Another issue of PCA is its diﬃculty of interpretation when PC is a
linear combination of a large number of variables.
Robust PCA and Sparse PCA have been pursued in the literature to overcome these
shortcomings. To achieve robustness of PCA, various Robust PCA approaches were pro-
posed: influence function techniques [41, 42, 43, 14], multivariate trimming [31], alternating
minimization [51], and random sampling techniques [24]. Recently, [8] proposed a low-rank
component recovery based approach, which is reportedly to attain strong performance gain
compared to previous methods; and [12] proposed an appealing algorithm using projection
pursuit such that a robust measure of variance is maximized in lower dimensional space.
On the other hand, to achieve better interpretation of each PC, Sparse PCA has recently
gained increasing popularity: a maximal variance approach [47], a regression framework [123],
greedy search and exact methods using branch-and-bound techniques [67], a convex relax-
ation/semidefinite programming approach [13], a regularized low-rank matrix approximation
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approach [93], penalized matrix decomposition based approach [115], and a generalized power
method [48]. Particularly, the method proposed by Witten and Tibshirani [115] was shown
to unify the approaches of Shen [93], Jolliﬀe [47], and Zou [123]. The main advantage of
Sparse PCA is to find sparse loadings so that each PC can be interpretable by a smaller
set of original features, which is essential in microarray analysis where thousands of features
often exist in the data. It also can be served as a good technique for an unsupervised feature
selection.
In this paper, we consider the situation that we have several similar studies and try
to compare several PCA results in parallel. By traditional PCA, each PC subspace is not
comparable. A na¨ıve solution for this problem is to project new data sets to previously
derived PC subspace. However, this approach is not eﬃcient in that it fails to utilize all
information from available data sets and not robust in that it depends totally on the quality
of target PC subspace. Better approaches should be the ones that can use all information
and are robust such that the driven PCs retain only informative common source of variance
and reveal the true separation among subjects.
Here, we propose two approaches that resolve the issues occurred by an individual PCA.
We hypothesize that several PCA results from compatible data sets have an advantage
to elucidate the common cause of variance throughout data sets regardless of individual
noise and heterogeneity of each study. Focusing on the commonness among studies is the
philosophy of what we are trying to do with MetaPCA by finding the “optimal common
subspace” in multiple studies.
Although some similar ideas have been in the literature, in our knowledge there was
no eﬀort to apply the concept of MetaPCA to genomic researches. Current literatures
regarding to genomic meta analysis are wholly focused on biomarker detection or gene set
enrichment analyses. Here, we have investigated the simultaneous dimension reduction of
multiple microarray studies using MetaPCA, and we show the usefulness of common subspace
in terms of dimension reduction for data visualization and classification.
The structure for the rest of the paper is as follows: In section 3.2, we propose two
MetaPCA optimization criteria (eigenvalue maximization and angle minimization approaches)
to find the common subspace. In section 3.3, we extend the preferred angle minimization
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approach to Robust PCA and Sparse PCA scenarios. In section 3.4, we apply the proposed
methods to five examples of microarray meta-analysis. The results are evaluated quanti-
tatively under data visualization and supervised machine learning framework. We provide
discussions and conclusions in section 5.
3.2 METAPCA
3.2.1 Common PC Subspace
The idea of comparing and combining subspaces generated by Principal Components (PC)
was first studied by Krzanowski [56]. The eigenvectors of several groups of individuals has
been compared by computing the angles between the subspaces spanned by the first k PCs of
each group. In addition, Krzanowski has proposed a simple estimate of the common subspace
as eigenvectors of the sum of sample covariance matrices and used it for the likelihood ratio
test of common principal components [57, 26]. This paper is based on these ideas of finding
common subspaces of several data sets; however, while those methods are focused on checking
and testing the similarities of covariance matrices of each data set, we are more interested in
developing integrative methods to represent the information gain by utilizing several relevant
data sets simultaneously in one analysis.
It is interesting to find informative linear combinations of features which can represent
multiple data sets simultaneously. This goal was described as a hypothesis for the test of
Common Principle Components (CPC) as follows [26, 57] :
Hb : L
tΩiL = Λi (i = 1, ..., K)
, where L is an orthogonal (p × p) matrix and the Λi is an diagonal matrix, and Ωi is the
sample covariance matrix of ith data set—there are total K number of studies considered.
Although this hypothesis is only the case when the number of features (p) is smaller than the
number of subjects (n), it can be easily extensible to the problems of when p is greater than
n. In that case, L should be an orthogonal matrix (p × n*), where the n* is the minimum
number of sample sizes among considered data sets.
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Here we alternatively define a meta-subspace as the common subspace of considered
data sets which can fulfill specific optimization criteria which are described in the next. And
we propose two basic methods to find meta-subspaces: the first one is aimed to find the
best subspaces which maximize the sum of variance of each data set, named as Eigenvalue
Maximization Approach; the second one is intended to find the best subspaces that minimize
the sum of squared cosine angle between meta-subspace and each individual subspace, named
as Angle Minimization Approach.
3.2.2 Eigenvalue Maximization Approach
The first approach to find a meta-subspace can be described as an optimization problem of
max
K￿
i=1
Λi = argmax
L
￿
LtΩiL
= argmax
L
Lt (
￿
Ωi)L (3.1)
max
K￿
i=1
wi
Λi
λi1
= argmax
L
Lt
￿
wi
Ωi
λi1
L (3.2)
, where λi1 and wi represent the largest eigenvalue and the weight of ith data set, respectively.
In the equation 3.2, the normalization of each covariance matrix was done by dividing with
its largest eigenvalue, λi1; so the largest possible value of max
K￿
i=1
Λi
λi1
is the same as the
number of studies, K; additionally, if a weight of ith study, wi, is obtained from the external
information, we can apply weighted sum of covariance matrices. The objective function 3.1
is a special form of 3.2 when all data sets have the equal weights and their scale diﬀerence
of covariance matrices are ignored so that no normalization is applied. The solution of
these optimization problem is the same as the one from the eigendecomposition of
￿
Ωi or￿
wi
Ωi
λi1
.
3.2.3 Angle Minimization Approach
The second approach is based on the geometrical interpretation of PCs [33]. Suppose we
have applied the K number of individual PCA analyses. Then we can get the K number of
eigenvector matrices Vi which has each dimension of p × ni; ni is less than or equal to the
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rank of each data set. It was shown that a vector L in the original p-dimensional data space
which minimizes the sum of all squared cosine angles between L and Vi can be calculated by
eigendecomposition of
￿
ViV ti [56]. The objective function can be denoted as follows:
argmax
L
Lt
￿￿
ViV
t
i
￿
L (3.3)
argmax
L
Lt
￿￿
wiViV
t
i
￿
L (3.4)
The objective function 3.3 is a special form of 3.4 when all data sets have the equal weights.
The solution simply can be derived by the eigendecomposition, and the first k’s of orthogonal
vectors L are the loadings of the meta subspace.
3.3 EXTENSION OF METAPCA
Additionally we extended the basic MetaPCA idea to more sophisticated and recent advances
of PCA, specifically Robust PCA and Sparse PCA.
3.3.1 Robust Angle Minimization Approach
Robust PCA was introduced as a generalization of PCA [61, 43]. Local optimal solution is
found by Projection Pursuit [40], and a robust measure of variance (e.g. IQR, MAD, and
Qn) is used as a projection index instead of variance. The advantage of Projection Pursuit
approach is its fast calculation when only first few PCs are considered. Specifically, we can
generalize objective function of PCA in terms of Projection Pursuit as follows:
vk = argmax
￿vk￿=1,vk⊥v1,...,vk⊥vk−1
PI(vtkx1, ..., v
t
kxn) (3.5)
, where vk is the kth eigenvector, and PI is called “projection index” and is the same as
variance in the case of usual PCA. The idea of robust PCA is simple that robust measure
of variance is used as projection index instead of variance.
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We adopted GRID algorithm [12] to find robust PC directions, V ∗i , of each data set and
simply replaced the objective function 3.3 as follows:
argmax
L
Lt
￿￿
V ∗i V
∗t
i
￿
L
The idea of GRID algorithm is to take advantage of the easy optimization of 3.5 in two
dimensional space. In two dimension, the objective function 3.5 is reduced to optimize
θ∗ = argmax
θ;−π/2≤θ≤π/2
PI (cosθVi + sinθej)
V ∗i = cosθ
∗Vi + sinθ∗ej
, where ej is the canonical basis vector (j = 1, ..., p).
3.3.2 Sparse Angle Minimization Approach
We extended the framework of [123] in the case of p ￿ n to incorporate multiple data sets
in a single SPCA procedure. The original objective function for a single component can be
written as follows:
argmin
α,β
￿X −XβαT￿2F + λ1￿β￿22 + λ2￿β￿1 subject to ￿α￿2 = 1
, where λ1,λ2 ≥ 0, and β and α are p-vectors; ￿ · ￿2F represents the squared Frobenius norm,
which is the sum of squared elements of the matrix.
Consider S number of microarray data (Xi; 1 ≤ i ≤ S), which each dimension is p number
of features in the rows and n number of samples in the columns.
The Meta Sparse PCA (Meta-SPCA) algorithm is as follows:
1. For the calculation of each meta-eigenvector Lj (1 ≤ j ≤ k), repeat from step 2 to 7
2. Let αij start at the first eigenvector of Xi (1 ≤ i ≤ S)
3. For fixed αij,
β∗ij =
￿
S￿
i=1
|αTijXTi Xi|
￿αTijXTi Xi￿
− λj
2
￿
+
Sign
￿
S￿
i=1
αTijX
T
i Xi
￿αTijXTi Xi￿
￿
βij =
β∗ij
￿β∗ij￿
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4. For fixed βij, compute SVD of XTi Xiβij, that is
XTi Xiβij = UiDiV
T
i , then αij = UiV
T
i
5. Repeat step 3 and 4 until convergence.
6. Apply Angle Minimization Method 3.3.1 to combine βij (1 ≤ i ≤ S) as follows:
argmax
Lj
Ltj
￿
S￿
i=1
βijβ
T
ij
￿
Lj
7. Project Xi to the orthogonal space of Lj as follows:
Xi := Xi
￿
I − LjLTj
￿
One of advantages of Meta-SPCA is that it can tolerate missing genes among data sets
since we can get zero values for the specified elements of αij from the augmented data set X∗i ,
which has the augmented features which are the union of features among all considered data
sets. We set the default value of λ as # of data sets√
# of augmented features
to consider each feature
and component equally. Additionally, we allowed one to set the number of features for the
analysis by deciding λ automatically.
3.4 APPLICATIONS
3.4.1 Data Description
3.4.1.1 Spellman data Spellman’s yeast cell cycle data [99] was utilized to evaluate the
performance of MetaPCA in terms of data visualization in two dimensional subspace. Bio-
logically, this data set should be considered as four independent studies using four diﬀerent
synchronization methods: α arrest (alpha), arrest of cdc15 or cdc28 temperature-sensitive
mutant (cdc15 and cdc28), and elutriation (elu). We filtered out genes which have overall
missing values ≥ 10% or log2 transformed standard deviation ≥ .45. 1025 genes were left,
and the number of time points in the experiments were 18, 24, 17, and 14 for alpha, cdc15,
cdc28, and elu, respectively. Additionally, we have imputed missing values using impute.knn
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function in R statistical language [83]. In a recent report, the impact of missing value impu-
tation to the downstream analysis such as classification was overall not severe [72]. We have
utilized this data set for 2D dimension reduction for visualization.
3.4.1.2 Prostate cancer data We have used two sets of prostate cancer studies for two
diﬀerent applications: The first set of four studies have three classes of subjects: normal,
primary, and metastasis [58, 107, 109, 122]. We used the first set for 2D dimension reduc-
tion for visualization. The second set of five studies have two classes of subjects: normal
and primary [58, 109, 111, 112, 122]. We used the second set for the supervised learning
(classification) evaluation. In both sets of data, we applied similar gene filtering and missing
value imputation so that we have 3056 and 3016 genes in each set, respectively.
3.4.1.3 Mouse metabolism data This dataset involves samples from three genotype
mice: wild-type (WT), LCAD knock-out (LCAD) and VLCAD knock-out (VLCAD). De-
ficiency of VLCAD is known to be related to a common energy metabolism disorder in
children. On the other hand, LCAD-deficient mice are known to have impaired fatty acid
oxidation and develop a disease similar to other disorders of mitochondrial fatty acid oxi-
dation. For each of the 12 mice (four mice in each genotype), four types of tissues (brown
fat, skeletal, liver and heart) were harvested and microarray experiments were performed
to study the expression changes across genotypes. We applied similar gene filtering and
missing value imputation so that we have 3175 genes left. We have used this data set for 2D
dimension reduction for visualization.
3.4.1.4 Brain cancer data We also obtained five brain cancer studies which have both
Anaplastic Astrocytoma (AA) and Glioblastoma multiforme (GBM) samples [104, 27, 79,
34, 80]. We applied similar gene filtering and missing value imputation so that we have 3004
genes left. The presumed goal of this meta-analysis is to find genomic diﬀerence between
AA and GBM. We have used this data set to evaluate MetaPCA for classification.
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3.4.2 Dimension Reduction For Data Visualization
The first application of simultaneous dimension reduction by MetaPCA is to find a common
low (2D or 3D) dimensional subspace in which all data set can be comparable. As a classical
example of visualization, we have considered Spellman yeast cell cycle data. The goal of
the analysis is to show cyclic patterns of subjects which are correspondent to the elapsed
time after initial cell cycle synchronization. Ideal figures are the ones which have two cyclic
patterns in the first three experiments (alpha, cdc15, and cdc28) and one cyclic pattern in
the last experiment (elu) from the known experimental conditions observed by microscope.
Figure 7 shows the results from non-meta approach for a comparison purpose. Columns and
rows represent each data and the subspace each data was projected, respectively. Diagonal
plots are from usual PCA results, meaning each data was projected to its own subspace. Oﬀ-
diagonal plots are projection of one study onto PC space generated by another study. For
instance, the top rows are results when each of the four studies was projected to the alpha
PC subspace. From the diagonal plots, we can tell that usual individual PCA may fail to
capture the true data structure; instead, the truth can be revealed by borrowing information
from the others. For example, cdc15 data in its own subspace had the worst result since it
was hard to find the expected cyclic patterns—Previously, the oscillating nature of cdc15
synchronized data has been observed and investigated [62]. However, if cdc15 is projected
to alpha space, we can observe clear cyclic patterns in the cdc15 data (See figure 7).
Direct projection approach—a study projected to a PC subspace of the other study—is a
good alternative to borrow information from other data set; however, there are shortcomings
that it does not perform real information integration. In the case of cdc15 example, since we
knew what patterns to look for, we could tell alpha space was the best projection for cdc15
data. In general, such cyclic prior information is not available. It is reasonable to expect
that automatic information integration of all four studies will identify a more informative
PC subspace and provide better visualization.
Figure 8 shows results from the four proposed MetaPCA methods. Strikingly, we found
clear cyclic patterns in almost every projection. Particularly, the improvement of cdc15
result was astounding. We could observe two clear cycles in alpha, cdc15, and cdc28 data,
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and one cycle in elu data. Moreover, all four projections in each row represent the exact same
projected space, allowing samples comparable between studies: we could even find that the
numbers and cyclic change of direction are also comparable between plots. It is interesting
that the Meta-SPCA results are based on only 40 genes (20 genes for each PC) and still
represent the cyclic patterns quite well.
As a second example of dimension reduction for visualization, we considered four prostate
cancer studies that have three types of samples: normal, primary, and metastasis. We
expect the distribution of subjects in these three classes to have a transitional change: from
normal to primary and then metastasis by disease severity. Figure 9 shows the result from
angle minimization approach. We projected all four studies to the driven PC subspace
by MetaPCA. As expected, we found a clear transitional pattern that the subjects were
clustered by classes from normal to metastasis via primary. Interestingly, the most important
separation among classes depends on the first meta PC, meaning that the first loading should
have important information regarding to genes that separate those three classes. Moreover,
the second PC separates well the metastasis from the others. From this example, we recognize
that the first two PCs are essential in separating the three classes, but due to the nature of
PCA, all genes have non-zero loading and the genes that are important for the separation
were not clear.
Meta-SPCA focuses to make those PCs interpretable in terms of smaller number of non-
zero loading genes. Figure 10 shows the result of Meta-SPCA using the same four prostate
data as in Figure 9. We arbitrarily selected the number of non-zero loading genes to be 20
for a concise interpretation of each PC, and dimension reduction identifies a list of genes
having strong relationship with prostate cancer. Genes with non-zero loading in the first two
PCs are shown in the Table 11. Most of the top genes (19 out of the first component and 19
out of the second component; marked by asterisk) were known related to prostate cancer in
PubMed and Google Scholar literature search. The advantage of Meta-SPCA is to find sets
of informative genes in a sequential manner so that their order of finding is correspondent to
the amount of overall information; in other words, the first set of genes which have non-zero
coeﬃcients in the first meta-PC loading are conceptually more informative genes, and the
genes in the second loading are the next.
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Figure 7: PCA result for Spellman data. Four data sets in Spellman yeast cellcycle data
were projected to four PC subspace which is denoted as y-axis. The diagonal plots are when
each data set is projected to its own PC subspace. The oﬀ-diagonal plots are when each data
was projected to PC subspaces generated from other data. Although we can observe some
cyclic patterns overall, some plots like cdc15 in the cdc15 subspace were hard to find cyclic
patterns. Interestingly, cdc15 in the alpha subspace shows better cyclic patterns. From this
result, cdc15 can be thought to be beneficiary for MetaPCA.
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Figure 8: MetaPCA result for Spellman data. Four data sets in Spellman yeast cellcycle
data were projected to four Meta-PC subspace which is denoted as y-axis. The first four
subspace are from each data set. The diagonal figure is when each data set is projected to its
own PC subspace. The first four oﬀ-diagonal figures are when each data was projected to PC
subspaces generated from other data. The last two figures represent meta subspace found
by eigen maximization and angle minimization approach, respectively. We can recognize the
bottom two results show better cyclic patterns.
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Figure 9: MetaPCA result for Prostate cancer data. Four prostate studies were
projected to the 2D meta-subspace found by angle minimization method. Each data set has
three disease classes, which is represented as diﬀerent colors. Subjects from each study are
represented as diﬀerent shapes. Regardless of diﬀerence in data sets, the same classes tend to
be clustered together. Moreover, it is for sure that there exists an order of distribution which
follows the disease classes, i.e. from normal to metastasis via primary. The first component
separates all three classes, and the second component separates metastasis from the others.
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Figure 10: MetaSPCA result for Prostate cancer data. Four prostate studies were
projected to the 2D meta-subspace found by Meta-SPCA. Each data set has three disease
classes, which is represented as diﬀerent colors. Subjects from each study are represented as
diﬀerent shapes. Regardless of diﬀerence in data sets, the same classes tend to be clustered
together. Moreover, it is for sure that there exists an order of distribution which follows the
disease classes, i.e. from normal to metastasis via primary.
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Table 11: First Two Loadings of Meta-SPCA
Gene Symbols PC1 PC2
ACTG2* -0.549 0.000
SLC14A1* -0.353 0.000
MYH11* -0.316 0.000
LTF* -0.297 0.000
CNN1* -0.277 0.000
PLN* -0.229 0.000
C10orf116* -0.190 0.000
KRT5* -0.169 0.000
PCP4* -0.168 0.000
FOSB* -0.166 0.000
MMP7* -0.150 0.000
MAOB* -0.136 0.000
FHL1* -0.134 0.000
LMOD1* -0.127 0.000
MFAP4 -0.119 0.000
ACTA2* -0.113 0.000
PTGS2* -0.108 0.000
CTGF* -0.099 0.000
FBLN1* -0.089 0.000
CYR61* -0.078 0.000
EDNRA* 0.000 -0.321
IGF1* 0.000 -0.314
TAGLN* 0.000 -0.311
RARRES1* 0.000 -0.309
CAV1* 0.000 -0.269
KCNMB1* 0.000 -0.259
ANGPT1* 0.000 -0.256
ATP1A2* 0.000 -0.244
SPARCL1* 0.000 -0.230
GAS1* 0.000 -0.228
TRIM29* 0.000 -0.212
ZIC2* 0.000 0.185
DPT* 0.000 -0.174
MEIS2* 0.000 -0.159
SLC22A3* 0.000 -0.156
SEMA3C* 0.000 -0.143
TPX2* 0.000 0.138
TOP2A* 0.000 0.129
CENPF 0.000 0.108
EGR1* 0.000 -0.100
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3.4.3 Numerical Evaluation of the Dimension Reduction For Visualization
The second application of MetaPCA is direct extension of the first application, more correctly
speaking it is a numerical evaluation of previous low dimensional reduction for visualization.
The question of the first application is how to measure the informative gain in a numerical
form. Although the cyclic pattern in cell cycle data is hard to evaluate quantitatively,
we can measure the information gain or loss by using some machine learning techniques
in some other cases. For this specific aim, we have used prostate cancer data and mouse
metabolism data which both have multi-class subjects. We applied the same procedure as the
first application—2D dimension reduction—, but instead of plotting results, we calculated
median silhouette width of subjects assuming the three class labels are composed of real
clusters. The rationale of this evaluation is based on the fact that an observer already
anticipates for some patterns of subject distribution if the subject classes are already known
as we can see in the cyclic pattern in the cell cycle data. Both prostate and metabolism data
are composed of three known class labels, so we could conclude that the good dimension
reduction for visualization should lead a good separation among those groups. Although
silhouette width is utilized usually in the clustering evaluation purpose, we can use it to
quantify the class separation in a robust way. The silhouette width measure can be defined
as follows:
s(i) =
b(i)− a(i)
max(a(i), b(i))
, where a(i) represents the average dissimilarity of subject i to all other objects of the assigned
cluster (A), and b(i) represents the minimum dissimilarity of the subject i to a subject in
the other cluster (C) such that C ￿= A. The range of silhouette width, s(i), is between -1
and 1. Zero width means the membership of the subject is in the border line. Larger width
means the better separation between classes.
The figure 11 shows the nice property of MetaPCA very well. Red dots represents the
cases when the driven meta subspace incorporates evaluation dataset, and blue dots means
the subspace did not utilize evaluated data. We can say that Heart and Skeleton data have
better results in their own space, and the performance does not hurt much by combining
with other data if their data themselves were used in the analysis, meaning red dots tend to
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have higher scores. In the other hand, the results of Liver and Fat improved a lot by using
PC subspace of others; especially if we compare two red dots in x = 1 or 4 in both Liver and
Fat cases, we can see the results improved about 3 times.
The figure 12 shows the result of prostate cancer example. Compared to previous figure,
overall MetaPCA performs did not improve much the outcome. The possible reason is those
data set is more heterogeneous so that information gain from other subspace was smaller
than the information loss, specifically Yu and Tomlins cases.
One of the common phenomena in both examples was the information gain experienced
in the single subspace projection (x=1) was a possible barometer for the performance of
MetaPCA. Specifically, the common result of Liver and Fat in metabolism data and Lapointe
and Varambally in prostate data was that they had better results in the projection to other
subspaces (See the dots in x=1, blue dots tend to be higher than the red dot). In this case,
MetaPCA performed better. We can compare the two red dots in x=1 and 4; the red dot in
x=4 was higher than the one in x=1.
This evaluation was a stepping stone to guide us to more fundamental question regarding
to supervised machine learning. Although silhouette width could be served as a quantitative
measure for class separation, we needed more sophisticated evaluation procedure to confirm
that the common PC subspace could lead a better classification.
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Figure 11: Silhouette score for MetaPCA in mouse metabolism data. Four mouse
metabolism data were projected to the 2D meta-subspace found by eigenvalue maximiza-
tion method. Red dots represents the cases when the driven meta subspace incorporates
evaluation dataset, and blue dots means the subspace did not utilize evaluated data. X
axis represents the number of studies included in each subspace generation. From 2 to 4
are based on MetaPCA, 1 is from single study. Y axis represents median silhouette width,
which measures the cluster tightness or separation.
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Figure 12: Silhouette score for MetaPCA in prostate cancer data. Four prostate
studies were projected to the 2D meta-subspace found by Meta-SPCA. Red dots represents
the cases when the driven meta subspace incorporates evaluation dataset, and blue dots
means the subspace did not utilize evaluated data. X axis represents the number of studies
included in each subspace generation. From 2 to 4 are based on MetaPCA, 1 is from single
study. Y axis represents median silhouette width, which measures the cluster tightness or
separation.
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3.4.4 Supervised Machine Learning (Classification)
The third application of MetaPCA is to see if the new common subspace between data set
could lead to the fundamental advantage to classify subjects better than the usual individual
classification approach. For this specific goal, we used 5 brain cancer data which compare
Anaplastic Astrocytoma (AA) and Glioblastoma multiforme (GBM) and 5 prostate cancer
data which compare normal and primary subjects. To obtain more reliable and robust
results, we have adopted leave-one-out cross-validation to test each test sample, specifically
we developed classifier based on learning samples without a test sample in each iteration
and meta-subspace was also re-generated based on learning samples. As the classification
method, we have utilized shrunken centroids regularized discriminant analysis (SCRDA)
[36], which produced reliable results with both original variables (genes) and derived PCs as
features. For the feature selection, we depended on the gene selection procedure of SCRDA
when we used genes as features; for the decision of number of PCs as features, we have used
the first 5 PCs and we also let SCRDA to find the best PC for each learning procedure. For
the evaluation of classification, we utilized Youden index [121], which can be calculated as
Sensitivity + Specificity − 1.
The figure 13 shows the result from the five brain cancer data. Overall, we observed
quite amount of improvement in accuracy for the classification, specifically Freije, Phillips,
and Sun were among the best results we had. In the figure, x=2 to x=5 represent the results
from MetaPCA; x=1 represents the direct projection to the individual data PC space; lastly
x=0 was incorporated for the comparison purpose when we have used the original variables
(genes) as features. Although the results of Gravendeel and Petalidis were not as good as
the others, their results still show that MetaPCA accomplished similar performance as the
single direct projection.
The figure 14 shows the result from the five prostate cancer data. Compared to brain
data, most studies had already greater classification accuracy individually—one of the pos-
sible reasons is that the primary cancer subjects were easy to classify from normal subjects.
As we saw in the figure 12, many studies were not well performed in the other subspace
than their own subspace (See red dots are higher than blue dots); especially, in the cases of
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Varambally, Wallace, and Yu, MetaPCA was performed somewhat less than the individual
PCA in its own subspace (i.e. red dot in x=1). However, the interesting observation which
we already observed in the previous section is that their direct individual projection to other
studies (i.e. blue dots in x=1) was already not good. As we mentioned before that the results
of the direct individual projection (i.e. when x=1) are determinants of the performance of
MetaPCA. The implication of this result is that we need more homogeneous studies in a
meta-analysis for better results.
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Figure 13: Youden index for MetaPCA in brain cancer data. Five brain cancer
studies were projected to the meta-subspace found by Meta-SPCA with 100 genes for each
PC. Red dots represents the cases when the driven meta subspace incorporates evaluation
dataset, and blue dots means the subspace did not utilize evaluated data. X axis represents
the number of studies included in each subspace generation. From 2 to 5 are based on
MetaPCA, 1 is from single study. Zero represents the case when classification is based on
original features, not on PCs. Y axis represents Youden index, which can be calculated as
sensitivity + specificity - 1
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Figure 14: Youden index for MetaPCA in prostate cancer data. Five prostate cancer
studies were projected to the meta-subspace found by eigenvalue maximization method. Red
dots represents the cases when the driven meta subspace incorporates evaluation dataset, and
blue dots means the subspace did not utilize evaluated data. X axis represents the number of
studies included in each subspace generation. From 2 to 5 are based on MetaPCA, 1 is from
single study. Zero represents the case when classification is based on original features, not
on PCs. Y axis represents Youden index, which can be calculated as sensitivity + specificity
- 1
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3.5 SIMULATIONS
We have also executed a couple of simulation studies to investigate comparative advantages
among our proposed methods and accuracy of important feature selection in Meta-SPCA.
For random cluster generation, we used the approach proposed by Qui and Joe [82] which
incoporates a cluster separation index measure. It also enables noisy variables and outlier
samples to be imposed for mimicking the complexity of real data sets. At first, we simulated
100 full data sets which has 300 samples from 3 clusters and 2100 gene features out of which
2000 are noise, and additionally we generated outlier samples from the uniform distribution.
We assumed 5 compatible studies, which were subsets of a full data set, had the same
cluster size (20 samples in each cluster). In reality, each study is not directly comparable
or combinable as in this case, but we simplified the simulation without considering further
perturbation in each study level; we can consider the direct combination of 5 subsets as the
best integration which leads to the most information gain. We summarized the mean of all
100 simulations of each category.
Figure 15 shows the simulation results including two basic MetaPCA methods (‘Angle’
and ‘Eigen’). As a comparison, PCA results in an individual study (‘Indiv’) and the maxi-
mum possible case (‘Max’), which includes all available samples and excludes noise features,
are shown. We used median silhouette width as the performance measure which is rep-
resented as y-axis. X-axis represents the degree of cluster separation which is defined as
J(a) = L2−U1U2−L1 , where Lk and Uk denote the lower and upper α/2 percentile of projected
cluster k, respectively. It is expected that the larger cluster separation index is, the larger
median silhouette width is. Figure 15 shows the 9 results by diﬀerent simulation settings
in the amount of noise features and outlier samples. As expected, overall patterns are to-
ward the upper right-hand side reflecting the very strong positive correlation between cluster
separation index and silhouette width. The PCA result using all samples shows the best pos-
sible performance which is located above all others in every circumstances. Individual PCA
shows its lack of power because of its smaller sample size; it locates in the bottom in most
of the cases. The two basic MetaPCA methods performed similar in between both usual
PCA cases in non-outlier cases (See the top row in Figure 15). The angle method performed
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well consistently regardless of the existence of outliers and noisy features; instead, the eigen
method suﬀered when there were outliers, particularly in the case when clusters are not well
separated (See the middle and bottom row in Figure 15). We can conclude that the angle
method is more robust than the eigen method to outlier samples and noisy features, and the
angle method is expected to be more practical in most of real situations. The result was
one of basis that we chose to extend only the angle method to incorporate Robust PCA and
Sparse PCA. Additionally, results of the eigen method were almost the same as the ones of
usual PCA approach with all sample as well as noise features (results are not shown).
Figure 16 shows the simulation results including two extended MetaPCA methods (‘Ro-
bustAngle’ and ‘SparseAngle’). As a comparison, the angle minimization MetaPCA (‘Angle’)
and maximum possible study (‘Max’) are shown. The robust angle method showed enough
robustness to noisy features and outlier samples (See the middle and bottom row in Figure
16). However, interestingly, the angle method outperformed the robust method in terms
of robustness as well as eﬃciency—the angle method had more stable performance in most
of the regions and better in most of realistic situations. The fact that the angle method
outshined the robust angle method in terms of robustness tells that the angle method has
already the innate robustness to outliers so that in most of real applications additional ro-
bust procedure is not necessary. On the other hand, the results of Meta-SPCA method were
showed to be sensitive to outliers. Considering its superb performance in non-outlier cases
(See the top row in Figure 16), its dramatic degradation of performance in the existence of
outliers is alarming; Sparse PCA methods based on the usual SVD technique should be used
carefully and robust SVD procedure should be incorporated in the case.
Figure 17 shows the eﬀectiveness of Meta-SPCA to find the true features. This simulation
assumed no existence of outlier samples. We used adjusted rand index (ARI) as the accuracy
evaluation measure of feature selection, which is defined as ARI = RIobs−E(RI)RImax−E(RI) , where RIobs,
RImax, and E(RI) are observed, maximum, and expected rand index, respectively, and RI =
sum of concordant pairs
total number of pairs . The best possible accuracy of feature selection was calculated by
Sparse PCA using the full data set, which is represented as dashed blue line with squares
located at the top in every cases. As another comparison purpose, the result of Sparse PCA
using individual subset of the data was represented dotted green line with triangles which
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are located at the bottom in most cases. The result of Meta-SPCA was represented as solid
red lines with circles. Overall conclusion of Figure 16 is that with proper setting of the
penalty parameter (λ), the true features can be chosen accurately without imposing many
noise features.
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Figure 15: Simulation results including the two basic MetaPCA methods. Y-
axis represents median silhouette width of true cluster samples. X-axis represents degree of
cluster separation. Each plot represents the result of a case which specifies the proportion
of outlier samples and noise features, e.g. the right bottom plot shows the result when
there exist 10% outliers and 20 times of noise features. Each line represents the result of
four analyses: maximum possible pca performance (‘Max’), two basic MetaPCA methods
(‘Angle’ and ‘Eigen’), and individual pca performance (‘Indiv’). Each point represents the
mean of 100 simulations.
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Figure 16: Simulation results including the two extended MetaPCA methods. Y-
axis represents median silhouette width of true cluster samples. X-axis represents degree of
cluster separation. Each plot represents the result of a case which specifies the proportion
of outlier samples and noise features, e.g. the right bottom plot shows the result when there
exist 10% outliers and 20 times of noise features. Each line represents the result of four
analyses: maximum possible pca performance (‘Max’), two extended MetaPCA methods
(‘RobustAngle’ and ‘SparseAngle’), and a basic MetaPCA method (‘Angle’). Each point
represents the mean of 100 simulations.
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Figure 17: Accuracy of feature selection in Sparse PCA and Meta-SPCA. Y-axis
represents adjusted rand index measuring the accuracy. X-axis represents diﬀerent penalty
parameter setting; the larger lambda is, the fewer features are selected. Each plot represents
the result of a case which specifies the degree of cluster separation and the proportion of
noise features, e.g. the right bottom plot shows the result when the clusters are very well
separated (0.7), and there exist 20 times of noise features. Each line represents the result
of three analyses: maximum possible SPCA performance (‘Max’), Meta-SPCA, and the
individual SPCA (‘Indiv’). Each point represents the mean of 100 simulations.
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3.6 DISCUSSIONS AND CONCLUSIONS
We consider the issue of information integration of multiple genomic (mainly microarray)
studies for PCA analysis. When multiple microarray studies are available, each study can
generate its own PC subspace. In this na¨ıve approach, the information contained in multiple
studies is not integrated and the projected data in each individual study are not compa-
rable. An ideal integrative PCA approach is to integrate information in multiple studies
and project data of all studies onto a single “optimal” PC subspace. In this paper, we
have proposed and compared two MetaPCA approaches: eigenvalue maximization approach
and angle minimization approach. We hypothesize that PCA results from multiple com-
patible studies used for integration have common cause of variation and underlying pattern
regardless of individual noises and heterogeneity in the studies. Our methods focus on the
commonness among studies to find the “optimal common projecting space”. Similar con-
cepts have been discussed in the statistical literature. For example, Krzanowski was the first
to compare and combine PC subspaces across studies [56]. Neuenschwandera and Flury [70]
discussed the theory underlying common PC models for dependent groups. These techniques,
however, have not been extended and applied to genomic data analysis since existing mi-
croarray meta-analyses literature mostly focus on detection of diﬀerentially expressed genes
or pathway enrichment analysis. To our knowledge, our paper is the first investigation of
PCA application in microarray meta-analysis.
So far we have proposed several approaches to obtain common PC subspace and evaluated
our methods in the context of dimension reduction for better visualization and classification.
Although most proposed methods are based on existing ideas, our novelty is that we showed
the information gain by combining multiple studies in several practical genomic data anal-
yses. In our knowledge, there was no similar attempt for the same goal as ours in genomic
research field yet.
From all the examples, we can observe the consistent patterns of result that make us to
get a glimpse of the performance of MetaPCA. When a study can be represented better or
quite similarly in the other studies’ PC subspace as original subspace, we observed that the
study could obtain more information gain so that it performed better in terms of visualization
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and classification. The striking example of cdc15 in Spellman cell cycle data and Liver or
Fat data in mouse metabolism are the best example of the argument. However, as we can
see in the prostate example, MetaPCA does not guarantee better performance all the time,
sometimes it cost more than benefits. Wallace or Yu in the classification are the examples of
such cases. Prostate cancers were reportedly very heterogeneous disease than other cancers
[89]; prostate cancer data may not be a good data for a meta-analysis. Although it is still
controversial that if all studies should be included in a meta-analysis or only the homogeneous
ones should be [23], our results support homogeneous study selection is very important pre-
process for the success of meta-analysis. In this context, our novel MetaQC [50] for genomic
meta-analysis could be a good tool to screen out inappropriate studies before meta-analysis
procedure.
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4.0 UNSUPERVISED COMBINATION OF CLINICAL AND GENE
EXPRESSION DATA ELUCIDATES PHENOTYPES IN ILD AND COPD
(It is expected to be published in a high profile medical journal)
It is necessary to define phenotypes of disease states to investigate their underlying
molecular mechanisms and develop new treatment strategies, therapeutics, and biomarkers.
Using chronic lung diseases which are commonly thought of as clinically distinct, we demon-
strate a computational approach to reverse phenotype patients using both clinical and gene
expression data. We acquired lung tissue, computed tomography, and clinical data on 472
subjects who were initially given a clinical diagnosis of either interstitial lung disease (ILD)
or chronic obstructive pulmonary disease (COPD). We performed unsupervised clustering
on patients with both phenomic and genomic expression data. We developed insightful fea-
ture visualization tools to explore and interpret the clusters. Pathway analysis and clinical
feature correlation are performed to characterize and annotate the identified intermediate
phenotypic patients. We showed the convergence/divergence patterns of disease phenotypes
in the integrated clustering by clinical and molecular features. Large number of patients was
in oﬀ-diagonal clusters which represent discrepancy between clinical and molecular pheno-
types. This is the first attempt that systematically integrate transcriptomic and phenomic
data in ILD and COPD. We identified new clusters of intermediate phenotypic patients that
may lead to improved understanding of these diseases and novel therapeutic approaches.
Our findings reflect that current clinical definitions and classification do not account for the
large number of patients having intermediate phenotypes or less common features that are
often excluded from clinical trials and epidemiology reports.
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4.1 INTRODUCTION
Chronic lung diseases aﬀect a significant portion of the population. Approximately 24 million
adults in U.S. have evidence of abnormal lung function. They go through 9.5 million oﬃce
and emergency room visits, 726,000 hospitalizations, and 119,000 deaths each year [66].
While the majority of these deaths can be attributed to chronic obstructive pulmonary
disease (COPD), the major smoking induced lung disease, more than 15,000 can be attributed
to idiopathic pulmonary fibrosis (IPF), a relentless, nearly always fatal fibrotic lung disease
also associated with smoking [73, 1].
The phenotypic description of these chronic lung disorders has been the focus of interest
of clinical research in the last decades of the 20th century. Clinical researchers dedicated
significant eﬀorts to define and identify the purest phenotypes of chronic lung diseases based
on physiology, radiology features, histopathology, significant negative findings and most im-
portantly prognosis [98, 32]. Such disease classifications create a unified vocabulary of lung
diseases that allows better communication between clinicians and researchers and simplifies
recruitment to clinical studies. While critically important and widely accepted, these clinical
definitions and classifications do not account for the large number of patients that present
with intermediate phenotypes or less common features. Such patients are often excluded
from clinical trials and epidemiology reports, a justified practice that limits our ability to
document the complexity and potential overlap of pathogenic processes and disease manifes-
tations shared by emphysema/COPD and IPF. Importantly, existing classifications do not
reflect recent important advances in radiologic imaging analysis and high-throughput gene
expression methods, techniques that potentiate investigators to fully capture the complexity
of a given individual’s phenotype.
High-throughput gene expression methods have been widely applied in cancer research
to identify known disease phenotypes or to define new ones. In pulmonary medicine, these
approaches have not been as widely applied, however recent studies evaluating IPF, COPD
or other lung diseases provide significant insight and promise in the application of similar
techniques to large cohorts with lung disease transcending usual disease boundaries [75,
81, 90, 91, 100, 116, 117, 119, 124]. While none of these studies directly compare IPF
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and emphysema/COPD and their subclasses, they do provide evidence that, in contrast to
the prevailing paradigm that places dysregulated activation of matrix degrading proteases
underlying emphysema in one extreme, and relentless extracellular matrix deposition in IPF
at the other extreme, these diseases may share activation of similar pathways, and potentially
similar mechanisms. While the investigators on this application completely agree that, in
their extremes, emphysema and IPF likely represent diﬀerent and divergent anatomical and
temporal responses to injury, we hypothesize that by applying gene expression profiling
and advanced computational approaches to a large enough and well characterized cohort
of samples of IPF and emphysema/COPD, we will identify disease-relevant gene expression
modules that are highly distinct, reproducible and characteristic of disease phenotypes that
go beyond current disease definitions.
To address our underlying hypothesis that gene expression patterns will identify diverging
and converging phenotypes in known phenotypes in IPF and COPD, we show gene expression
signatures that globally characterize COPD and IPF. Modular integration of data from
multiple sources using gene expression, clinical data, radiological and physiological data
may reduce the eﬀects of individual variation. The significance of our works is the innovation
that looks at IPF and COPD, not as phenotypic extremes, but as multiple syndromes that
may be the end result of overlapping as well as diverging mechanisms. The availability of
the molecular phenotypes within and across disease boundaries will have the potential to
liberate pulmonary clinical research from the need to focus on the most divergent phenotype,
and instead will allow researchers to focus on mechanistically relevant disease molecular
phenotypes.
4.2 MATERIALS AND METHODS
We acquired flash frozen lung tissue, computed tomography (CT) data, and clinical data on
472 subjects from the Lung Tissue Research Consortium (LTRC). These subjects were ini-
tially given a clinical diagnosis of either interstitial lung disease (ILD) or chronic obstructive
pulmonary disease (COPD) based on their clinical, pathologic, and radiographic data (217
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Table 12: Correlation of diﬀerent data types
Quantitative Ordinal Nominal
Quantitative Pearson Biserial/Polyserial Point Biserial/MCC1
Ordinal Biserial/Polyserial Spearman/Tetrachoric Rank Biserial
Nominal Point Biserial/MCC1 Rank Biserial Phi/PCC2
1 Multivariate correlation coeﬃcient
2 Pearson’s contingency coeﬃcient
COPD and 255 ILD). Extensive clinical variables (∼1,000) were obtained by questionnaires
(demographic, medical history, family history, smoking history, concomitant therapy, symp-
tom, SF-12 health, St. Georges respiratory, environmental, occupational), tests (six-minute
walk test, cardiopulmonary exercise test, PFT, blood test, CT scan), and diagnosis reports
(central and local pathology, clinical report). Gene expression data were obtained through
the use of the two diﬀerent Agilent microarray platforms. We applied loess normalization
after matching probe ids between platforms. The number of matched genes are 15,966.
We filtered out clinical variables to choose informative and representative ones in each
category (i.e. less missing values, closer to continuous). We defined the distance between
variables as 1− ρij, where ρij is the correlation coeﬃcient between two variables i and j. To
calculate the correlation between diﬀerent data types, we applied several correlation models
as in the table 12. After several iterations, we selected 30 clinical variables.
We applied k-means sparse clustering [114] with 3 clusters to find informative genes. We
obtained 4,291 genes which have positive contribution. We applied k-medoids [106] with
k=3 using either clinical variables or genes as features. For an eﬀective representation of the
convergence/divergence patterns of clinical and molecular phenotypes, we have developed 2D
or 1D visualization tools which show the transition of features of a cluster in the intuitive
and interpretable way. We have modified GEDI plot [20] to incorporate clinical features
and gene expressions in the same space using multi-dimensional scaling (MDS) [5, 88]. To
find the common and augmented feature space, we combined clinical variables and genes
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so that we obtained a 4,321×4,321 dissimilarity matrix and applied MDS to find the best
2 or 1 dimensional configuration of features. After 2D projection, we divided the derived
space to 10x10 grid subspace and calculated median standardized score of the cell (clinical
or genes) for each patient. For cluster visualization, we summarized medians of each grid of
given cluster members. For 1D projection, we applied spaghetti plots that fit a cubic spline
to standardized scores of each cluster subjects (clinical or genes). Since the similar features
are closely located, we can interpret each figure based on a cluster of features. Moreover
clinical variables and genes can be used together for the interpretation interactively. Principal
component analysis (PCA) was applied to project subjects in 2 dimensional clinical feature
space. To enhance interpretation, we juxtaposed clinical features on top of derived PC
subspace (PCA biplot). The coordinate of a feature corresponds to the amount of correlation
that the feature has with each derived principal component.
For validation of cluster analysis, we divided samples to two groups. The training group
was composed of the first two batches (305 samples), and the testing group was the third
batch (167 samples). Feature filtering was applied to the training set using k-means sparse
clustering [114] with k=3, and 4402 genes were selected (30 clinical variables were reused).
Aforementioned cluster analysis and visualization methods were applied to the training set.
We applied a separate cluster analysis to the testing set using the same features found by
training set. To validate the testing set result, we utilized the 2D and 1D cluster visualization
of training set as the gold standard, i.e. we reused the feature projection result of training
set to visualize the clusters found by the testing set. The rationale of this validation study
is that if the clustering result found by training set was not a coincidence, it should be
reproducible with independent data.
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4.3 RESULTS
4.3.1 Clinical Feature Filtering
We applied clinical feature visualization and variable clustering method to find representative
variables using the distance matrix calculated by various correlation models in Table 12.
Figure 18 shows an example of clinical feature visualization. Each cell represents the degree
of pair-wise similarity between two variables, which is defined as |corij|, where i and j
represent two variables. We have generated many figures like Figure 18, which were served
to help us to understand clinical data set we have and to promote us to communicate
between physicians and statisticians. Using the same distance matrix, which is 1 − |corij|,
we also applied a hierarchical clustering method to find clusters of variables such as Figure
19. We manually reviewed variables cluster by cluster and chose 1 or 2 clinically important
representative variables in a cluster. We iteratively applied this approach and decided to
include 30 informative and clinically important variables.
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Figure 18: An example of clinical feature visualization. Each cell represents the degree
of pair-wise similarity (correlation coeﬃcient) between two variables.
72
Figure 19: An example of clinical variable clustering.
73
4.3.2 Cluster Validation Analysis
One of concerns in pure computational approach is over-fitting. Although we didn’t assume
any models to fit, we still wanted to confirm that our methods are robust enough to reproduce
the clusters we found. Here, the reproduction of clusters means the characteristics of each
cluster can be reproduced in terms of clinical phenotypes and gene expression patterns.
So we utilized our novel visualization tools to show the validation of clustering. Figure 20
shows the result of cluster validation analysis by 2 dimensional gene expression visualization.
Each cell represents a cluster of patients which found by two separate cluster analyses using
gene expression (x-axis) and clinical phenotypes (y-axis). Each pixel represents the median
intensity of standardized gene expression in a group of genes similarly expressed. Red color
represents over expression, and blue represents under expression. We observed testing set
can reproduce the training set result very well as we can see the similar pattern of heatmaps
between training and testing sets; specifically the clusters of genes in the left area are over-
expressed in COPD clusters by gene expression, and the ones in the right area are over-
expressed in ILD clusters. There was a little discrepancy in the middle column that in the
training set the mixed cluster was closer to ILD cluster and in the testing set to COPD
cluster; one of probable reasons can be found from the major clinical diagnosis composition
of clusters in Figure 21 that the mixed cluster has more ILD proportion in the learning
set and more COPD proportion in the testing set. Figure 22 represents the same cluster
validation result using 1 dimensional gene expression visualization. In this figure, similarly
expressed genes are located closely in the x-axis, and y-axis represents standardized gene
expression intensity. Each line represents cubic spline estimate of gene expression in a cluster
of patients which found by two separate cluster analyses using gene expression (three levels
of vertical cells) and clinical phenotypes (three levels of diﬀerent colors in a cell). As the 2D
visualization, we could confirm that the cluster analysis based on training set is reproducible.
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Figure 20: Cluster validation by 2D gene expression visualization. Each cell repre-
sents a cluster of patients which found by two separate cluster analyses using gene expression
(x-axis) and clinical phenotypes (y-axis). Each pixel represents the median intensity of stan-
dardized gene expression in a group of genes similarly expressed. Red color represents over
expression.
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Figure 21: Major clinical diagnosis in each cluster for cluster validation. Each
cell represents a cluster of patients which found by two separate cluster analyses using gene
expression (x-axis) and clinical phenotypes (y-axis). Each pie chart represents the proportion
of major clinical diagnosis in the patients of the specified cluster.
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Figure 22: Cluster validation by 1D gene expression visualization. Each line rep-
resents cubic spline estimate of gene expression in a cluster of patients which found by two
separate cluster analyses using gene expression (three levels of vertical cells) and clinical
phenotypes (three levels of diﬀerent colors in a cell). Y-axis represents standardized gene ex-
pression (z-score), and x-axis represents genes which are ordered by their pair-wise distance.
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4.3.3 The Convergence/Divergence of Clinical and Molecular Phenotypes
One of main aims of this study is to show a transitional pattern of both clinical and molec-
ular phenotypes so that we could focus on clusters which have discrepancy between those
phenotypes. Figure 23 shows the change of phenotypic pattern among clusters: the plot a)
represents pattern of gene expression that three clusters found by gene expression are diﬀer-
entiated clearly; however, the plot c), which represents change of clinical phenotypes, does
not show stable and clear distinction among clusters. One of main reasons is the existence
of many missing values in some patients and the sparsity of clinical variables in derived
2D space. Traditionally, only few clinical variables such as Pre FEV1 and the ratio of Pre
FEV1/FVC were mainly used for those disease classification; however, we showed the ne-
cessity of incorporating gene expression as features for better classification. For instance,
in b) cluster 1 and 2 are composed of similar proportion of ILD and COPD patients, and
expectedly, in c) their clinical phenotypes are very similar; however, in a) gene expression
pattern of two clusters are very diﬀerent, suggesting that they are diﬀerent diseases in spite
of their similarity in clinical phenotypes. In this context, we need further study to find a
correlation between their gene expression and disease progression or treatment eﬃcacy.
Figure 24 shows one dimensional representation of the same information in Figure 23.
The goal of this figure is to have integrated interpretation of clinical phenotypes and gene
expression in a cluster. Both plots in the figure share the same x-axis, but y-axis ap-
plies only relevant scores which are standardized score in clinical variables in the above,
and standardized expression intensity in the below. One example of integrated interpreta-
tion is that the clusters 3, 6, and 9 have similar gene expression patterns, especially they
have important over-expressed set of genes—MMP11, COMP, MMP3, MMP14, MMP7, and
MMP1—which are known IPF signature genes; moreover, those genes are closely related
with important clinical phenotypes—Reticular infiltrates, Lung reticular volume, and ratio
of Pre FEV1/FVC—which are known important CT and lung test features of IPF.
To our knowledge, it is the first time that a systematic sub-classification of two major
chronic lung disease is done by using both clinical and molecular features with large number
of well defined cohort.
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Figure 23: The Convergence/Divergence of Clinical and Molecular Phenotypes.
a) Each cell represents a cluster of patients which found by two separate cluster analyses
using gene expression (x-axis) and clinical phenotypes (y-axis). Each pixel represents the
median intensity of standardized gene expression in a group of genes similarly expressed.
Red color represents over expression. b) Each pie chart represents the proportion of major
clinical diagnosis in the patients of the specified cluster. c) Similar to a), but each pixel
represents the median value of standardized clinical variables nearby. d) The cluster 9 in
c) was enlarged to show that the color patterns are interpretable by given clinical features
juxtaposed on top of the figure in d). Since a) and c) are comparable, gene clusters in a)
which are related to interesting clinical phenotypes in c) can be matched and interpretable
interactively. (e.g. gene expressions and clinical phenotypes are highly correlated in the
cluster 9, which has the largest IPF proportion)
79
Figure 24: One Dimensional Representation of the Figure 23. Both x-axis’s are
exactly the same, derived by 1D projection of pair-wise distance structure using both clinical
and molecular features. They are ordered by their similarity. a) In the x-axis, only clinical
variables are presented for separate interpretation. Y-axis represents standardized value of
each clinical variable. Each line represents a cubic spline estimate of scores in the specified
cluster. b) Only genes are presented in the x-axis. Y-axis is the standardized gene expression.
X-axis in both figures are comparable, so one can find a set of highly correlated reciprocal
features.
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4.4 DISCUSSION AND CONCLUSIONS
We showed in a systematic way that there exist groups of patients who have intermediate
phenotypes and mixed molecular signatures between COPD and ILD, which are known as
phenotypic extremes. It can be described as a phenomenon that both clinical and molecular
phenotypes have diﬀerent convergence/divergence patterns in each cluster. For instance, in
Figure 23, clusters 1 and 9 have convergent pattern of clinical and molecular phenotypes fit-
ting to current knowledge and disease definition: Clinical phenotypes were highly correlated
to molecular phenotypes in “pure” disease groups. However, the existence of other clusters
which have divergent pattern of clinical and molecular phenotypes support the argument
that current disease definition is too narrow to incorporate intermediate phenotypic groups
of patients. Particularly, cluster 1 and 2 have the similar diagnosis proportion and cluster
sizes and turned out to have very diﬀerent molecular signatures; cluster 7 has the most di-
vergent pattern which has strikingly similar gene expression with the typical COPD cluster
(cluster 1) in spite of its diverse composition of diagnoses. It implies that similar molecular
processes can cause various clinical phenotypes that supports our hypothesis that ILD and
COPD are not phenotypic extremes but multiple syndromes that may be the end result of
overlapping as well as diverging mechanisms. For the first time, we showed that molecular
phenotyping can be successfully incorporated with clinical phenotyping to identify a cluster
of various homogeneous patients.
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5.0 FINAL DISCUSSION AND FUTURE DIRECTION
We have investigated novel methodologies to show the advantages of proper genomic meta-
analysis. Although study selection is necessary and justifiable practice, no known systematic
and quantitative criteria exist. Our contribution is to reveal the pitfalls of inappropriate
selection criteria and to oﬀer a tool which can be used as an objective evidence of study
inclusion/exclusion criteria. MetaPCA is a direct beneficiary of MetaQC. The success of
simultaneous dimension reduction and discovery of eﬀective common PC subspace depend
on the homogeneity of given studies. Although our proposed approach is incorporated with
robust methodologies, we observed homogeneous studies lead to better results. MetaPCA is
a significant attempt to seek a new direction in genomic meta-analysis. We expect increased
popularity of meta-analysis in various other machine learning techniques including meta
clustering and meta discriminant analysis. The direct extension of our works is to apply
them to diﬀerent data types such as RNAseq and methylation data. Particularly, the data
type in RNAseq is discrete instead of continuous which is the case in microarray data. More
investigation is needed to check whether any assumption in our methods is aﬀected. However,
the philosophy and the goal in our proposed approaches still prevail.
The third component of this thesis was not about horizontal data integration but about
vertical integration in that it was dealing with diﬀerent data types exist in diﬀerent levels.
Over the last several decades, dominant disease definitions in chronic lung diseases were
based on a few clinical phenotypes such as pre-FEV1 or the ratio of pre-FEV1 and pre-FVC.
However, it has been well known that clinicians often faced atypical phenotypic manifestation
in some patients which usually have both characteristics of ILD and COPD. There were no
systematic eﬀorts to reveal the phenotypic convergence/divergence using well defined large
cohort. With the help of integrative clustering analysis and cluster visualization methods, we
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showed and validated the existence of transitional pattern of disease phenotypes in clinical
and gene expression data. The direct extension of our findings is to incorporate follow-up
studies on the identified groups of patients in terms of disease progression and drug eﬃcacy.
After that, we could define novel subtypes of the two diseases using important clinical and
molecular features which may lead to a novel prediction model or diagnostic tool.
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